<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PPAR Res</journal-id><journal-id journal-id-type="publisher-id">PPAR</journal-id><journal-title>PPAR Research</journal-title><issn pub-type="ppub">1687-4757</issn><issn pub-type="epub">1687-4765</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19197366</article-id><article-id pub-id-type="pmc">2632771</article-id><article-id pub-id-type="doi">10.1155/2008/103167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Rat Urinary Bladder Carcinogenesis by  Dual-Acting  PPAR<italic>&#x003b1;</italic> + <italic>&#x003b3;</italic> Agonists</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Oleksiewicz</surname><given-names>Martin B.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Southgate</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Iversen</surname><given-names>Lars</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Egerod</surname><given-names>Frederikke L.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Molecular Toxicology, Novo Nordisk A/S, 2760 Maalov, Denmark</aff><aff id="I2"><sup>2</sup>Jack Birch Unit of Molecular Carcinogenesis, Department of Biology, University of York, York YO10 5YW, UK</aff><aff id="I3"><sup>3</sup>Biopharm Toxicology and Safety Pharmacology, Novo Nordisk A/S, 2760 Maalov, Denmark</aff><author-notes><corresp id="cor1">*Martin B. Oleksiewicz: <email>moleksiewicz@intercell.com</email></corresp><fn fn-type="other"><p>Recommended by Dipak Panigrahy</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>28</day><month>1</month><year>2009</year></pub-date><volume>2008</volume><elocation-id>103167</elocation-id><history><date date-type="received"><day>14</day><month>8</month><year>2008</year></date><date date-type="accepted"><day>7</day><month>10</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Martin B. Oleksiewicz et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Despite clinical promise, dual-acting activators of PPAR<italic>&#x003b1;</italic> and <italic>&#x003b3;</italic> (here termed PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists) have experienced high attrition rates in preclinical and early clinical development, due to toxicity. In some cases, discontinuation was due to carcinogenic effect in the rat urothelium, the epithelial layer lining the urinary bladder, ureters, and kidney pelvis. Chronic pharmacological activation of PPAR<italic>&#x003b1;</italic> is invariably associated with cancer in rats and mice. Chronic pharmacological activation of PPAR<italic>&#x003b3;</italic> can in some cases also cause cancer in rats and mice. Urothelial cells coexpress PPAR<italic>&#x003b1;</italic> as well as PPAR<italic>&#x003b3;</italic>,  making it plausible that the urothelial carcinogenicity of PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists may be caused by receptor-mediated effects (exaggerated pharmacology). Based on previously published mode of action data for the PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonist ragaglitazar, and the available literature about the role of PPAR<italic>&#x003b1;</italic> and <italic>&#x003b3;</italic> in rodent carcinogenesis, we propose a mode of action hypothesis for the carcinogenic effect of PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists in the rat urothelium, which combines receptor-mediated and off-target cytotoxic effects. The proposed mode of action hypothesis is being explored in our laboratories, towards understanding the human relevance of the rat cancer findings, and developing rapid in vitro or short-term in vivo screening approaches to faciliate development of new dual-acting PPAR agonist compounds.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>Selective small molecule agonists for the peroxisomeproliferator-activated receptors <italic>&#x003b1;</italic> and <italic>&#x003b3;</italic> are used to treat metabolic disorders. PPAR<italic>&#x003b1;</italic> agonists (fibrates) are used for their blood lipid lowering effects, andPPAR<italic>&#x003b3;</italic> agonists (thiazolidinediones) for their insulin sensitizing effects [<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B3">3</xref>]. Additionally, dual-acting agonists for PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic>, here termed PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic>agonists, have been shown to have clear therapeutic advantages over selectivePPAR agonists in animals as well as humans [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>]. Unfortunately, a high percentage of PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists exhibited carcinogeniceffect during preclinical safety testing in rats and mice [<xref ref-type="bibr" rid="B2">2</xref>&#x02013;<xref ref-type="bibr" rid="B7">7</xref>]. Basedon carcinogenicity findings for 6 PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> and 5 PPAR<italic>&#x003b3;</italic> anonymous developmentalcompounds in rats and mice, the FDA concluded that &#x0201c;PPAR agonists aremultispecies, multistrain, multisex, multisite carcinogens&#x0201d; (<xref ref-type="table" rid="tab1">Table 1</xref>) [<xref ref-type="bibr" rid="B8">8</xref>]. TheFDA further concluded that &#x0201c;mechanistic data to explain mode of action fortumour formation is not available. Tumours sites are consistent with the knowndistribution of PPAR receptors. Oncogenic potency correlates with PPAR agonistpotency. A receptor-mediated mechanism cannot be ruled out&#x0201d; [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Accordingly, the attrition rate amongst developmentalPPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists has been high, with amongst others tesaglitazar (Galida),naveglitazar (LY519818), muraglitazar, ragaglitazar, farglitazar, andimiglitazar (TAK559) recently being discontinued due to clinical cardiac,kidney or liver toxicity, or preclinical findings [<xref ref-type="bibr" rid="B3">3</xref>&#x02013;<xref ref-type="bibr" rid="B5">5</xref>]. These6 developmental PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists represent different nonthiazolidinedionechemical structures, with different balances between PPAR<italic>&#x003b1;</italic> and <italic>&#x003b3;</italic> activation [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B9">11</xref>]. For 4 dual-acting agonists, preclinical carcinogenicity findings have beenpublished muralitazar, ragalitazar, tesaglitazar, and naveglitazar arenongenotoxic by standard tests. Muralitazar caused gallbladder adenomas (malemice), adipocyte neoplasms (male and female rats), and urinary bladder tumours(male rats) [<xref ref-type="bibr" rid="B10">27</xref>]. Ragalitazarcaused urinary bladder and renal pelvis tumours (male and female rats) [<xref ref-type="bibr" rid="B11">28</xref>&#x02013;<xref ref-type="bibr" rid="B13">30</xref>]. Naveglitazar caused urinary bladder tumours in female rats, with the evaluationof carcinogenicity in male rats affected by poor survival [<xref ref-type="bibr" rid="B14">31</xref>]. Tesaglitazar caused mesenchymal sarcomas (male and female rats) [<xref ref-type="bibr" rid="B15">13</xref>].</p><p>The involvement of PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> in cancer pathogenesishas been reviewed extensively [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B16">32</xref>&#x02013;<xref ref-type="bibr" rid="B20">36</xref>]. WhilePPAR<italic>&#x003b1;</italic> activation is clearly carcinogenic in rodents [<xref ref-type="bibr" rid="B21">9</xref>, <xref ref-type="bibr" rid="B16">32</xref>, <xref ref-type="bibr" rid="B17">33</xref>],the rodent PPAR<italic>&#x003b3;</italic> data are controversial, and it appears that rodent PPAR<italic>&#x003b3;</italic>activation may have oncogenic as well as tumour suppressor activity, likelydepending amongst others on cellular and physiological  contexts [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B21">9</xref>, <xref ref-type="bibr" rid="B18">34</xref>, <xref ref-type="bibr" rid="B20">36</xref>]. Further, potential interactions between rodent PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> in coexpressing cells have, to our knowledge, essentially not been examined at all. Finally,the human relevance of rodent data is unknown, as there is indication that, forexample, PPAR<italic>&#x003b3;</italic> agonists may have clinical benefit against certain human cancerssuch as lung cancer [<xref ref-type="bibr" rid="B22">37</xref>].</p><p>We base the present manuscript on the observation that inrats, toxicity of dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists appears to target cells coexpressingPPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic>, resulting in a qualitatively different target organ profilefrom that of selective PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> agonists (<xref ref-type="table" rid="tab1">Table 1</xref>). Then, we review theliterature with the aim of constructing a mode of action hypothesis for thecarcinogenic effect of ragaglitazar in the rat urothelium. Due to thecomplexity of the available data, this is by definition speculative, andinvolves weighing of probablilities rather than combining facts, but thepresented mode of action hypothesis forms the basis for our own researchregarding the mechanisms by which PPAR agonists induce cancer in the raturothelium.</p></sec><sec sec-type="section" id="sec2"><title>2. COMPARING NORMAL PHYSIOLOGY OFPPARs IN THE RAT AND HUMAN UROTHELIUM:TOWARD SAFETY PPARallelograms</title><p>Expression of PPAR transcripts by urothelium occurs earlyin development and is conserved across species [<xref ref-type="bibr" rid="B24">17</xref>, <xref ref-type="bibr" rid="B23">38</xref>],implying a tissue-specific role. In normal human urothelium, PPAR<italic>&#x003b3;</italic> is most intensely expressed in the terminally differentiatedsuperficial cell layer [<xref ref-type="bibr" rid="B25">39</xref>, <xref ref-type="bibr" rid="B26">40</xref>], andexpression is decreased in high-grade urothelial cell cancer [<xref ref-type="bibr" rid="B27">41</xref>],further indicating a potential role in urothelial cytodifferentiation.</p><p>Normal human urothelium isolated from urologicalspecimens from patients with no history of urothelial cancer can be routinelyestablished in serum-free primary cell culture and maintained through multipleserial subcultures (typically 6&#x02013;10) as cell lineswith a finite lifespan [<xref ref-type="bibr" rid="B28">42</xref>, <xref ref-type="bibr" rid="B29">43</xref>]. These cultures show a regenerative phenotypeand do not spontaneously express gene/proteins associated with late/terminaldifferentiation [<xref ref-type="bibr" rid="B28">42</xref>, <xref ref-type="bibr" rid="B29">43</xref>].</p><p>Activation of PPAR<italic>&#x003b3;</italic>  by agonists(troglitazone or rosiglitazone) in finite cultures of normal human urothelialcells (NHU cell cultures) has been shown to induce expression of gene/proteinmarkers associated with late/terminal urothelial differentiation, includinguroplakins, cytokeratins, and tight junction constituents [<xref ref-type="bibr" rid="B26">40</xref>, <xref ref-type="bibr" rid="B30">44</xref>&#x02013;<xref ref-type="bibr" rid="B32">46</xref>]. Theproposed differentiation-inducing mechanism is via PPAR<italic>&#x003b3;</italic>-dependent transduction of intermediarytranscription factors, including HNF3<italic>&#x003b1;</italic>, IRF-1, and FOXA1, and the induction ofdifferentiation is specifically blocked by PPAR<italic>&#x003b3;</italic> antagonists, or siRNAs against PPAR<italic>&#x003b3;</italic>,  IRF-1,and FOXA1 [<xref ref-type="bibr" rid="B32">46</xref>]. Theinduction of differentiation in NHU cell cultures by troglitazone requiresinhibition of PI3K/AKT or MEK1/ERK signalling pathways downstream of EGFR [<xref ref-type="bibr" rid="B30">44</xref>], whichin NHU cells is important for driving proliferation [<xref ref-type="bibr" rid="B33">47</xref>]. Inhibition of the downstream EGFR pathways resulted in dephosphorylation ofPPAR<italic>&#x003b3;</italic>  [<xref ref-type="bibr" rid="B30">44</xref>]. Theinteraction between the signalling pathways that regulate differentiation (PPAR<italic>&#x003b3;</italic>) and proliferation (EGFR) in urothelium maylie at the heart of regulating urothelial homeostasis and the switch fromquiescent to regenerative phenotypes.</p><p>While PPAR<italic>&#x003b3;</italic> activation in NHU cell cultures inducesdifferentiation [<xref ref-type="bibr" rid="B26">40</xref>, <xref ref-type="bibr" rid="B30">44</xref>&#x02013;<xref ref-type="bibr" rid="B32">46</xref>], someselective PPAR<italic>&#x003b3;</italic> and most dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists causebladder cancer in rats (<xref ref-type="table" rid="tab1">Table 1</xref>) [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B34">48</xref>]. Also,a recent study showed that the specific PPAR<italic>&#x003b3;</italic> agonist rosiglitazone is a strongpromoter of hydroxybutyl(butyl)nitrosamine-induced bladder cancer in rats [<xref ref-type="bibr" rid="B35">49</xref>]. It isunknown whether this apparent contradiction represents a species difference, ora difference between in vivo and invitro experimental systems. Also, it is well known that the outcome ofPPAR<italic>&#x003b3;</italic> signalling is highly context specific, that is, diametrally oppositebiological effects can be seen in different situations [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B18">34</xref>, <xref ref-type="bibr" rid="B20">36</xref>]. Resolution of the different observations in NHU cell cultures in vitro and rat tissue in vivo is ofobvious relevance for elucidating the bladder carcinogenicity mechanisms ofdual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists in rats, and elucidating the human relevance ofthe rat bladder cancer findings (<xref ref-type="table" rid="tab1">Table 1</xref>). Using a standard &#x0201c;safetyparallelogram&#x0201d; approach for extrapolating the human relevance of rodentfindings, PPAR signalling should be compared between rat urothelial cells in vivo and in vitro, and alsobetween rat and human urothelial cells invitro.</p><p>In this vein, we have recently compared normal rat andhuman urothelia in situ as wellas following culture, and confirmed urothelial expression of all three PPARs and the RXR<italic>&#x003b1;</italic> and RXR<italic>&#x003b2;</italic> isoforms by immunolabelling. Some differencein relative expression and localisation of the different isoforms was apparent betweenspecies [<xref ref-type="bibr" rid="B36">18</xref>]. Also,rat urothelium exhibited a higher proliferative pool of Ki67 positiveurothelial cells than did human urothelium [<xref ref-type="bibr" rid="B36">18</xref>], inagreement with a high percentage of G2/M cells in rat urothelium [<xref ref-type="bibr" rid="B13">30</xref>]. Incontrast, human urothelial cells insitu appear arrested in G0/G1 [<xref ref-type="bibr" rid="B33">47</xref>]. Therelevance of these differences between rat and human urothelia for PPARsignalling is at present unknown. However, PPAR and RXR expression patterns wereretained by both NHU and cultured normal rat urothelial cells, opening thepossibility that normal urothelial cell culture systems may be used to comparePPAR signalling between rats and humans [<xref ref-type="bibr" rid="B36">18</xref>, <xref ref-type="bibr" rid="B28">42</xref>, <xref ref-type="bibr" rid="B29">43</xref>, <xref ref-type="bibr" rid="B37">50</xref>].</p><p>In short, most knowledge about PPAR<italic>&#x003b3;</italic> signalling in urothelium stems from NHU cellcultures [<xref ref-type="bibr" rid="B26">40</xref>, <xref ref-type="bibr" rid="B30">44</xref>&#x02013;<xref ref-type="bibr" rid="B33">47</xref>], andvery little information exists regarding PPAR<italic>&#x003b1;</italic> signalling response in the urothelium [<xref ref-type="bibr" rid="B38">51</xref>, <xref ref-type="bibr" rid="B39">52</xref>]. Nevertheless,based on the observation that bladder cancer appears overrepresented fordual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists (<xref ref-type="table" rid="tab1">Table 1</xref>), and direct experimental indication ofcross-talk between PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> in urothelium as well as other cell types [<xref ref-type="bibr" rid="B42">19</xref>, <xref ref-type="bibr" rid="B11">28</xref>, <xref ref-type="bibr" rid="B40">53</xref>&#x02013;<xref ref-type="bibr" rid="B43">55</xref>], ourcurrent hypothesis is that simultaneous activation of PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> could in some way modulate theproliferation/differentiation balance, contributing to carcinogenesis ofdual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists in the rat urothelium (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec><sec sec-type="section" id="sec3"><title>3. RANKING THE POSSIBLE MECHANISMS FORTHE CARCINOGENIC EFFECTS OF RAGAGLITAZARAND NAVEGLITAZAR IN THE RAT UROTHELIUM:WHAT IS PPARt OF THE PPARcel?</title><p>Ragaglitazar is a phenyl propanoic acid derivative withdual PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonist activity [<xref ref-type="bibr" rid="B44">56</xref>, <xref ref-type="bibr" rid="B45">57</xref>]. In 2-yearrat carcinogenicity assays, papillomas and carcinomas originating from thetransitional epithelial (urothelial) lining of the urogenital tract wereobserved for all groups receiving ragaglitazar, for both male and femaleanimals [<xref ref-type="bibr" rid="B12">29</xref>]. Theurothelial papillomas and carcinomas were observed in the urinary bladder, ureters,and renal pelvis [<xref ref-type="bibr" rid="B12">29</xref>]. Inmouse 2-year studies, one urinary bladder tumour was observed in a high-dosemale mouse [<xref ref-type="bibr" rid="B12">29</xref>]. Thehigher sensitivity of rats than mice to urothelial tumours induced byragaglitazar may be shared by other dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists (<xref ref-type="table" rid="tab1">Table 1</xref>).</p><p>Four nonexclusive mechanisms were initially consideredfor the urothelial tumours in ragaglitazar-treated rats (<xref ref-type="fig" rid="fig1">Figure 1</xref>): (i) a receptor-mediated effect of theparent compound, with carcinogenesis caused by activation of PPAR<italic>&#x003b1;</italic> and <italic>&#x003b3;</italic>transcription factors in the urothelium, that is, an exaggeratedpharmacological effect, (ii) a genotoxiceffect of metabolites of the parent compound (the parent compound itself is notgenotoxic), (iii) a cytotoxiceffect of parent compound or metabolites on urothelium, causing cancer due to aproliferation-driven chronic wound healing response, (iv) formation of urinary solids (urolithiasis) due to urinarychanges induced by parent compound or metabolites, leading to cancer due tochronic irritation of the urothelium.</p><p>It is well known that certain agents cause urinarybladder cancer in rodents secondary to urolith formation [<xref ref-type="bibr" rid="B34">48</xref>], andthat such carcinogenic effect is not relevant for humans because in humansuroliths do not predispose for bladder cancer [<xref ref-type="bibr" rid="B46">60</xref>]. Aurolithiasis-mediated mechanism would be expected to affect primarily (albeitnot exclusively) male rats due to the lower efficacy with which males voiduroliths and act primarily in the ventral part of the urinary bladder (<xref ref-type="fig" rid="fig1">Figure 1</xref>) [<xref ref-type="bibr" rid="B34">48</xref>]. Therefore, a urolithiasis-mediated mechanism was ruled out primarily by theobservation that ragalitazar caused tumours also in the ureters and renalpelvis, a conclusion supported by the occurrence of bladder tumours in females [<xref ref-type="bibr" rid="B12">29</xref>]. Indetailed follow-up examinations in ragaglitazar-treated animals, urinarycalculi were not detected during necropsy, no microcrystals were found toadhere to the urothelium by scanning electron microscopy, sediments were notincreased in the urine by light microscopy, no significant changes wereobserved in urinary composition [<xref ref-type="bibr" rid="B12">29</xref>]. Likewise, and naveglitazar did not cause changes in urinary composition [<xref ref-type="bibr" rid="B14">31</xref>].</p><p>To explore mechanism (ii), profiling of urinary metabolites by mass spectroscopy andexamination of DNA damage in urothelium isolated from ragaglitazar-treated ratsby single-cell gel electrophoresis assay (COMET) were performed. Ragaglitazarexhibited multiple metabolites in rat urine (&#x0003e;10), but there was low overallurinary excretion, and DNA damage was not observed in the urinary bladder ofragaglitazar-treated rats [<xref ref-type="bibr" rid="B12">29</xref>].</p><p>In summary, neither urinary calculi nor genotoxic damageby urinary metabolites could explain the carcinogenic effect of ragaglitazar inthe rat urothelium. As a working hypothesis, we, therefore, assumed thatragaglitazar caused urothelial cancers in rats by a receptor-mediated effect ofthe parent compound (mechanism (i)above), which may be exacerbated by a cytotoxic effect of parent compound ormetabolites on urothelium, promoting achronic wound healing response (mechanism (iii) above). This mode of action hypothesis (<xref ref-type="fig" rid="fig3">Figure 3</xref>),comprising 2 nonexclusive mechanisms (<xref ref-type="fig" rid="fig1">Figure 1(b)</xref>, (i) and (iii))was in agreement with coexpression of PPAR<italic>&#x003b1;</italic> and <italic>&#x003b3;</italic> by the urothelium [<xref ref-type="bibr" rid="B24">17</xref>, <xref ref-type="bibr" rid="B36">18</xref>, <xref ref-type="bibr" rid="B23">38</xref>],with the known propensity of various PPAR agonists to exhibit cytotoxic effects[<xref ref-type="bibr" rid="B20">36</xref>, <xref ref-type="bibr" rid="B47">61</xref>, <xref ref-type="bibr" rid="B48">62</xref>],and with the known positive correlation between cytotoxic and carcinogeniceffects for some small molecule drugs [<xref ref-type="bibr" rid="B49">63</xref>, <xref ref-type="bibr" rid="B50">64</xref>]. Similarly, it was concluded for naveglitazar-induced bladder cancer in ratsthat a mechanism involving a direct effect of the compound on PPARs in theurothelium should be considered [<xref ref-type="bibr" rid="B14">31</xref>].</p></sec><sec sec-type="section" id="sec4"><title>4. EARLY BIOMARKERS FOR RAGAGLITAZAR ANDNAVEGLITAZAR ACTIONS IN THE RAT UROTHELIUM</title><p>The mode of action hypothesis detailed above (<xref ref-type="fig" rid="fig3">Figure 3</xref>)predicted that very early (precancerous) changes should occur in the urotheliumof ragaglitazar-dosed rats, reflecting exaggerated pharmacology and/orcytotoxicity of the compound.</p><p>To test whether this was the case, a method was developedwhere a lysing guanidine buffer is injected in situ in the bladder of anaesthetised treated animals,providing selective lysis of the urothelial layer and minimizing the risk ofpreparation artefacts (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>Such urothelial lysates from male rats dosed orally for 2-3 weeks wereexamined by a combination of microarray, RT-PCR, and Western blotting methods [<xref ref-type="bibr" rid="B11">28</xref>]. Wefound that within 4 days of ragaglitazar treatment, the transcription factorEgr-1 was strongly upregulated in the bladder urothelium of animals treatedwith 50 mg/kg/day ragaglitazar [<xref ref-type="bibr" rid="B11">28</xref>]. Interestingly, Egr-1 was not upregulated in the bladder urothelium of ratsdaily receiving either 8 mg/kg/day rosiglitazone (a selective PPAR<italic>&#x003b3;</italic> agonist) or200 mg/kg/day fenofibrate (a selective PPAR<italic>&#x003b1;</italic> agonist), but appeared upregulatedin the bladder urothelium of rats receiving a combination of rosiglitazone  and fenofibrate [<xref ref-type="bibr" rid="B11">28</xref>]. Thesignificance of these findings is being confirmed, but the data support that inrats orally dosed with ragaglitazar,expression of Egr-1 was acutely induced in the bladder urothelium, and coactivationof PPAR<italic>&#x003b3;</italic> and PPAR<italic>&#x003b1;</italic> was required forthis. Other early changes observed in the bladder urothelium involvedphosphorylation of the S6 ribosomal protein, and the c-jun transcription factor[<xref ref-type="bibr" rid="B11">28</xref>].</p><p>Microscopically, hypertrophy (increased cell size),hyperplasia (increased number of cells), and increased proliferation (increasedDNA synthesis, measured by BrdU incorporation) were observed in the bladder andkidney pelvis urothelium of ragaglitazar-dosed rats, within 3 weeks of dailyoral dosing [<xref ref-type="bibr" rid="B11">28</xref>&#x02013;<xref ref-type="bibr" rid="B13">30</xref>]. Because urothelial hypertrophy is difficult to quantitate by light microscopy,we utilized flow cytometry as well as DNA/protein measurements to show thatwithin 2-3 weeks of oraldosing with 5&#x02013;50 mg/kg/dayragaglitazar, the bladder urothelium underwent diffuse, generalizedhypertrophy; that is, the hypertrophy affected the whole urothelial cellpopulation [<xref ref-type="bibr" rid="B13">30</xref>]. Urothelial hypertrophy was also observed in the kidney pelvis [<xref ref-type="bibr" rid="B12">29</xref>, <xref ref-type="bibr" rid="B13">30</xref>]. Finally, hypertrophy and hyperplasia were likewise observed in the urotheliumof ragaglitazar-dosed dogs and monkeys [<xref ref-type="bibr" rid="B12">29</xref>]. Interestingly, in naveglitazar-dosed rats, urothelial hypertrophy was theearliest change, seen at 27 weeks, followed by urothelial hyperplasia at 53&#x02013;79 weeks [<xref ref-type="bibr" rid="B14">31</xref>].</p></sec><sec sec-type="section" id="sec5"><title>5. POTENTIAL RELEVANCE OF EARLY UROTHELIALCHANGES FOR LATER CANCER DEVELOPMENT</title><p>The c-jun transcription factor is a recognized oncogene [<xref ref-type="bibr" rid="B51">65</xref>] andhas been implicated in human bladder cancer development [<xref ref-type="bibr" rid="B52">66</xref>, <xref ref-type="bibr" rid="B53">67</xref>]. Futhermore, increased c-jun activity has been linked to bladder cancerdevelopment in mice exposed to the model bladder carcinogen arsenic [<xref ref-type="bibr" rid="B52">66</xref>, <xref ref-type="bibr" rid="B53">67</xref>].</p><p>Egr-1 (Zif268) is a zinc finger transcription factormediating a broad range of cellular responses such as proliferation,differentiation, apoptosis, neuronal plasticity, and neovascularization [<xref ref-type="bibr" rid="B54">68</xref>&#x02013;<xref ref-type="bibr" rid="B57">71</xref>]. Egr-1is closely related to the WT1 Wilms' tumour suppressor, with these two zincfinger transcription factors being able to  be bound to the same DNA sequence, but exertingopposite effects on transcription [<xref ref-type="bibr" rid="B58">72</xref>&#x02013;<xref ref-type="bibr" rid="B60">74</xref>]. Giventhe importance of the WT1 transcription factor for kidney development [<xref ref-type="bibr" rid="B61">58</xref>], it isperhaps unsurprising that Egr-1 also has functional roles through the length ofthe urogenital tract. Egr-1 expression is regulated during kidney development [<xref ref-type="bibr" rid="B62">75</xref>], andpostnatally, Egr-1 is involved in control of kidney function [<xref ref-type="bibr" rid="B63">76</xref>], andbladder urothelium function [<xref ref-type="bibr" rid="B64">77</xref>&#x02013;<xref ref-type="bibr" rid="B66">79</xref>]. Egr-1overexpression and interaction with the WT1 Wilms' tumour suppressor may beinvolved in the pathogenesis of nephroblastoma [<xref ref-type="bibr" rid="B58">72</xref>&#x02013;<xref ref-type="bibr" rid="B60">74</xref>]. Further, the bladder and prostate epithelia are contiguous and have commonembryological origin [<xref ref-type="bibr" rid="B61">58</xref>, <xref ref-type="bibr" rid="B67">80</xref>, <xref ref-type="bibr" rid="B68">81</xref>],and interestingly, Egr-1 is absolutely required for the development of prostatecancer in a mouse model [<xref ref-type="bibr" rid="B69">82</xref>, <xref ref-type="bibr" rid="B70">83</xref>]. Egr-1has also been implicated in human prostate cancer development [<xref ref-type="bibr" rid="B71">84</xref>]. In vitro, Egr-1 is induced in humanurothelial cancer cells treated with the model bladder carcinogen arsenic [<xref ref-type="bibr" rid="B53">67</xref>], andEgr-1 physically associates with BLCA-4, a recognized marker of bladder cancer,in human urothelial tumour cells [<xref ref-type="bibr" rid="B72">85</xref>, <xref ref-type="bibr" rid="B73">86</xref>]. c-junand Egr-1 have also been shown to physically interact in rat spontaneouspheochromocytoma PC12 cells [<xref ref-type="bibr" rid="B56">70</xref>]. Importantly, it is currently unknown whether the phosphorylation of c-jun andinduction of Egr-1 in the urothelium of ragaglitazar-treated rats  correspond to increasedactivity of these transcription factors.</p><p>Hypertrophy (increased cell size) is a surrogateparameter for increased protein synthesis (translation) [<xref ref-type="bibr" rid="B74">87</xref>]. Intriguingly, phosphorylation of the ribosomal S6 protein is known to stimulateprotein translation, and S6 phosphorylation is also linked to cellular size [<xref ref-type="bibr" rid="B75">88</xref>&#x02013;<xref ref-type="bibr" rid="B80">93</xref>]. Thus,the increased S6 phosphorylation and hypertrophy observed in the urothelium ofragaglitazar-treated rats may be causally linked [<xref ref-type="bibr" rid="B11">28</xref>, <xref ref-type="bibr" rid="B13">30</xref>]. Asmentioned, hypertrophy was also the earliest change in the urothelium ofnaveglitazar-dosed rats [<xref ref-type="bibr" rid="B14">31</xref>].</p><p>Urothelial hypertrophy can also be induced by noncarcinogenicagents [<xref ref-type="bibr" rid="B81">94</xref>]. Nevertheless, both hypertrophy and increased protein synthesis have beenreported as  precancerous changesfollowing exposure to model bladder carcinogens [<xref ref-type="bibr" rid="B82">95</xref>], andtranslational deregulation is increasingly being recognized as playing a keyrole in cancer development [<xref ref-type="bibr" rid="B75">88</xref>&#x02013;<xref ref-type="bibr" rid="B77">90</xref>, <xref ref-type="bibr" rid="B80">93</xref>, <xref ref-type="bibr" rid="B83">96</xref>].</p><p>In summary, while completely speculative, a causal linkbetween early urothelial changes (hypertrophy, S6 phosphorylation, c-junphosphorylation, Egr-1 induction) and later urothelial cancer development inragaglitazar-treated rats appears possible (<xref ref-type="fig" rid="fig3">Figure 3</xref>). As mentioned above,early urothelial hypertrophy was alsoobserved in naveglitazar-dosed rats [<xref ref-type="bibr" rid="B14">31</xref>].</p></sec><sec sec-type="section" id="sec6"><title>6. CYTOTOXIC AND NONGENOMIC EFFECTS OFPPAR AGONISTS IN VITRO</title><p>Surprisingly, structurally different agonists for PPAR<italic>&#x003b1;</italic>and PPAR<italic>&#x003b3;</italic> show a common propensity for PPAR-independent (off-target) effects,particularly relating to growth inhibition (cytostasis) and cell death in avariety of cell types [<xref ref-type="bibr" rid="B20">36</xref>, <xref ref-type="bibr" rid="B48">62</xref>, <xref ref-type="bibr" rid="B84">97</xref>, <xref ref-type="bibr" rid="B85">98</xref>]. The mechanisms for the nongenomic actions of PPAR agonists are unknown, but mayhave parallels in, for example, the nongenomic actions of steroid hormones [<xref ref-type="bibr" rid="B86">99</xref>].</p><p>We found that exposure of NHU cultures to ciglitazone or troglitazone(PPAR<italic>&#x003b3;</italic>) or ragaglitazar (PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic>) rapidly induced apoptosis in NHU cells [<xref ref-type="bibr" rid="B47">61</xref>]. Theseeffects were independent of p38 or pERK activation and were not seen with fenofibrate(PPAR<italic>&#x003b1;</italic>), L165041 (PPAR<italic>&#x003b2;</italic>), or rosiglitazone (PPAR<italic>&#x003b3;</italic>). Proapoptotic agonists induced rapid,sustained increases in intracellular calcium that were attenuated by removal ofextracellular calcium, indicating the involvement of store-operated calciumentry. Proapoptotic agonists also induced cell membrane disruption, loss ofmitochondrial membrane potential, and activation of caspases-9 and -3. PPAR agonist-induced apoptosis was partiallyattenuated by store-operated calcium channel inhibitors, but was unaffected byPPAR<italic>&#x003b3;</italic> antagonists. This demonstrates thatstructurally different PPAR agonists activate intrinsic apoptotic pathways in normalhuman urothelial cells in a PPAR-independent manner. Interestingly, PPARagonists associated with hepatotoxicity and carcinogenicity in vivo also exhibited the most severecytotoxicity profile in vitro, comprisingapoptosis and sustained increases in intracellular calcium [<xref ref-type="bibr" rid="B47">61</xref>]. Recently, sustained increases inintracellular calcium were linked to transactivation of the EGF receptor bynongenomic actions of PPAR<italic>&#x003b3;</italic> agonists [<xref ref-type="bibr" rid="B85">98</xref>].</p><p>Because the nongenomic cytotoxic actions of PPAR agonistsappear to be relatively cell type independent [<xref ref-type="bibr" rid="B48">62</xref>], andbecause it is well known that cytotoxic effect in vitro may positively correlate with a carcinogenic effect in vivo [<xref ref-type="bibr" rid="B49">63</xref>, <xref ref-type="bibr" rid="B50">64</xref>], wecurrently favor incorporating the NHU cytotoxicity findings [<xref ref-type="bibr" rid="B47">61</xref>] into amode of action hypothesis for the carcinogenic effect of dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonist in the rat urothelium (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Interestingly, normal urothelial cells are more sensitive to the nongenomic cytotoxic actions of PPAR agoniststhan are transformed urothelial cells [<xref ref-type="bibr" rid="B27">41</xref>]. Thus,nongenomic cytotoxic actions could hypothetically contribute not only toinitiating the carcinogenic process (detailed in <xref ref-type="fig" rid="fig3">Figure 3</xref>) but also toselecting transformed urothelial cells.</p><p>Intriguingly, and further complicating matters, somestudies suggest that PPAR<italic>&#x003b3;</italic> agonists previously associated with nongenomiccytotoxicity at high concentration can at lower concentrations stimulateproliferation and prevent apoptosis [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B18">34</xref>, <xref ref-type="bibr" rid="B87">100</xref>&#x02013;<xref ref-type="bibr" rid="B90">103</xref>]. Thisstimulatory effect does not occur for PPAR<italic>&#x003b3;</italic> agonists in NHU cultures [<xref ref-type="bibr" rid="B91">104</xref>], butweak stimulatory effects and bell-shaped responses have been observed withunsaturated fatty acids in NHU cultures [<xref ref-type="bibr" rid="B92">105</xref>]. Inshort, because bell-shaped responses from activation of a specific PPAR may berelated to agonist characteristics, and because detection of weak mitogenicresponses in cell cultures (at low drug concentrations) may technically be moredifficult than detection of cytotoxicity in cell cultures (at high drugconcentrations), the phenomenon of bell-shaped response curves encompassing mitogenic as well as cytotoxiceffects may be underreported in studies of PPAR agonist effects in vitro.</p></sec><sec sec-type="section" id="sec7"><title>7. RECEPTOR-MEDIATED CARCINOGENESISIN RAT UROTHELIUM BY DUAL-ACTING <italic>&#x003b1;</italic>+<italic>&#x003b3;</italic>AGONISTS SUCH AS RAGAGLITAZAR:PPARadigm OR PPARadox</title><p>The dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonist muraglitazar also causedurothelial tumours in rats, but in this case it was concluded that aurolithiasis-mediated mechanism was responsible [<xref ref-type="bibr" rid="B10">27</xref>, <xref ref-type="bibr" rid="B12">29</xref>, <xref ref-type="bibr" rid="B93">114</xref>, <xref ref-type="bibr" rid="B94">115</xref>]. In contrast, uroliths were not involved in the urothelial cancers seen inragaglitazar or naveglitazar-treated rats [<xref ref-type="bibr" rid="B12">29</xref>, <xref ref-type="bibr" rid="B14">31</xref>]. Furthermore, tesaglitazar did not induce bladder cancers in rats [<xref ref-type="bibr" rid="B15">13</xref>]. Thereasons for the difference in carcinogenic potential in the rat urothelium forthe four dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists muraglitazar, ragaglitazar, naveglitazar,and tesaglitazar are unknown. It is tempting to speculate that the differencesin PPAR affinity and selectivity between these three PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists influencecarcinogenic potential in the rat urothelium [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B9">11</xref>]. PPAR<italic>&#x003b1;</italic>and PPAR<italic>&#x003b3;</italic> activation profiles can be compiled for muraglitazar, ragaglitazar,naveglitazar, and tesaglitazar from different studies [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B5">5</xref>]. However, in order to evaluate whether PPAR affinity and selectivity correlateswith carcinogenicity, we believe it would be required to compare thesedual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic>  agonists in the same study, preferably using urothelial cells and monitoring theactivation of endogenous PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> which are coexpressed in this celltype. Technically, this could, for example, be done by, in urothelial cells,separately monitoring expression of genes known to be activated by PPAR<italic>&#x003b1;</italic> on onehand, and genes known to be activated by PPAR<italic>&#x003b3;</italic>, on the other (PPAR-regulatedgenes listed in [<xref ref-type="bibr" rid="B95">15</xref>]). Suchdata unfortunately do not exist. Nevertheless, the findings in <xref ref-type="table" rid="tab1">Table 1</xref> suggestthat while agonists with a high degree of PPAR<italic>&#x003b3;</italic> selectivity (i.e., specific PPAR<italic>&#x003b3;</italic> agonists) can cause bladdercancer in rats, they may be less prone to do so than are agonists with a lowerdegree of PPAR<italic>&#x003b3;</italic> selectivity (i.e., dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists). Thisinterpretation of the data in <xref ref-type="table" rid="tab1">Table 1</xref> is speculative (disregards, e.g., doselevel or PPAR agonist efficacy differences between the animal trials with thelisted agents), but is plausible given the relatively unique coexpression ofPPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> by urothelial cells. Thus, the hypothesis deserves furtherexploration, that combined PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> activation, by agents with low PPAR<italic>&#x003b3;</italic>selectivity or high doses of agents with high PPAR<italic>&#x003b3;</italic> selectivity, may predisposeto urothelial cancer in rats by receptor-mediated mechanisms (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>It has beenproposed that it is unlikely that any of the urothelial cancers observed inrats treated with dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists are due to receptor-mediatedeffects (exaggerated pharmacology) [<xref ref-type="bibr" rid="B34">48</xref>]. Wehave a different interpretation of the available data: it is clear thatactivation of PPAR<italic>&#x003b1;</italic> can cause tumours in rats and mice (<xref ref-type="table" rid="tab1">Table 1</xref>) [<xref ref-type="bibr" rid="B21">9</xref>], andwhile more controversial, activation of PPAR<italic>&#x003b3;</italic> can at least in some cases causecancer in rats and mice (<xref ref-type="table" rid="tab1">Table 1</xref>) [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B18">34</xref>, <xref ref-type="bibr" rid="B20">36</xref>]. Of special interest is the recent finding that selective PPAR<italic>&#x003b3;</italic> agonists such asrosiglitazone can promote hydroxybutyl(butyl)nitrosamine-induced bladder cancerin rats [<xref ref-type="bibr" rid="B35">49</xref>] (<xref ref-type="table" rid="tab1">Table 1</xref>). Thus, it is plausible that the carcinogenic effect of dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic>agonists in cells coexpressing PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> (<xref ref-type="table" rid="tab1">Table 1</xref>) may be due toreceptor-mediated mechanisms (exaggerated pharmacology). Further, it has beendescribed that PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> agonists may exhibit synergistic effects incells coexpressing PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> [<xref ref-type="bibr" rid="B42">19</xref>, <xref ref-type="bibr" rid="B11">28</xref>, <xref ref-type="bibr" rid="B40">53</xref>&#x02013;<xref ref-type="bibr" rid="B43">55</xref>]. Thus,the hypothesis of receptor-mediated carcinogenicity (carcinogenicity due toexaggerated pharmacology) would predict that in rat tissue coexpressing PPAR<italic>&#x003b1;</italic>and PPAR<italic>&#x003b3;</italic>, dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonistsmay have a higher propensity for carcinogenic effect than selective PPAR<italic>&#x003b1;</italic> andPPAR<italic>&#x003b3;</italic> agonists alone, which in fact appears to be the case (<xref ref-type="table" rid="tab1">Table 1</xref>). Endothelial cells also coexpress PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> [<xref ref-type="bibr" rid="B96">20</xref>], andsynergy between PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> in the endothelium has been described [<xref ref-type="bibr" rid="B42">19</xref>], buthemangiosarcoma frequencies appear comparable between mice treated withdual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists and selective PPAR<italic>&#x003b3;</italic> agonists (<xref ref-type="table" rid="tab1">Table 1</xref>). This mayrelate to differences between mouse urothelium and endothelium in PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic>expression, signalling, and/or cross-talk.</p><p>Specifically, we are not aware of any data that a priori disqualifies areceptor-mediated carcinogenicity mechanism for dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists inthe rat urothelium [<xref ref-type="bibr" rid="B34">48</xref>]. Forexample, (human) urothelium does not appear to receive growth/differentiationcues from the urine [<xref ref-type="bibr" rid="B25">39</xref>] andhence low urinary excretion of PPAR agonists does not rule outreceptor-mediated carcinogenic effects. Also, the well known in vitro cytotoxic effects of PPARagonists [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B20">36</xref>, <xref ref-type="bibr" rid="B48">62</xref>],including ragaglitazar [<xref ref-type="bibr" rid="B47">61</xref>], aregenerally mediated by nongenomic (off-target) mechanisms, that is, do not ruleout receptor-mediated carcinogenic effects in vivo. In fact, our current working hypothesis for ragaglitazar is that exaggerated pharmacology andnongenomic cytotoxicity may occur simulaneously and together promote cancerdevelopment in the rat urothelium (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Finally, the overrepresentationof bladder cancers in male rats seen with some dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists issometimes presented as an argument against receptor-mediated carcinogeniceffects [<xref ref-type="bibr" rid="B34">48</xref>]. However, current data suggests that there are gender differences in theexpression of all PPAR isoforms, in a variety of species and tissue, including theurinary bladder [<xref ref-type="bibr" rid="B97">108</xref>&#x02013;<xref ref-type="bibr" rid="B102">113</xref>]. Moreover, our hypothesis implies that the male rat may represent an acceleratedtumour model, as any cytotoxicity/damage to the urothelium will provokeurothelial regeneration and thus promote a receptor-mediated carcinogeniceffect (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>A key issue for the future will be how to distinguishbetween &#x0201c;receptor-mediated&#x0201d; and &#x0201c;nonreceptor-mediated&#x0201d;urinary bladder carcinogenicity mechanisms in rat experiments. Most simply, wesuggest that receptor-mediated (exaggerated pharmacology) carcinogenicitymechanisms may be suspected for dual-acting agonists that inducecarcinogenicity-relevant biomarkers in the rat urothelium with rapid kinetics(i.e., following a minimum of repeated oral doses) and with equal distributionin the dorsal and ventral bladder domes [<xref ref-type="bibr" rid="B11">28</xref>&#x02013;<xref ref-type="bibr" rid="B13">30</xref>]. Themaximal doses in this type of study could logically be the same as those usedfor 2-year rat carcinogenicity studies (heart weight increases of approx. 25%at 13 weeks have been suggested to identify the maximum tolerated dose for2-year rodent oncogenicity studies) [<xref ref-type="bibr" rid="B8">8</xref>], andlower doses may allow evaluation of nongenomic (off-target) effects on the biomarker endpoints [<xref ref-type="bibr" rid="B13">30</xref>]. Further refinement may be accomplished by including PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> antagonists[<xref ref-type="bibr" rid="B95">15</xref>, <xref ref-type="bibr" rid="B103">116</xref>, <xref ref-type="bibr" rid="B104">117</xref>],inactive analogs [<xref ref-type="bibr" rid="B85">98</xref>], or,more speculatively, modulation of PPAR expression in the bladder by siRNAapproaches [<xref ref-type="bibr" rid="B105">118</xref>].</p><p>Adding 1% NH<sub>4</sub>Clto rat feed induces systemic acidosis, measurable directly by reduced blood pH,reduced blood [HCO<sub>3</sub><sup>&#x02212;</sup>], andincreased blood [H<sup>+</sup>]  as well as indirectly by, for example,increased urinary Ca<sup>++</sup> and phosphorus excretion due to boneresorption [<xref ref-type="bibr" rid="B106">119</xref>]. Asurine acidification also occurs, adding 1% NH<sub>4</sub>Cl to rat feed is sometimes used to evaluate whether ratbladder carcinogenesis is urolith-mediated [<xref ref-type="bibr" rid="B12">29</xref>, <xref ref-type="bibr" rid="B34">48</xref>, <xref ref-type="bibr" rid="B93">114</xref>, <xref ref-type="bibr" rid="B94">115</xref>]. However, urine acidification by feeding rats NH<sub>4</sub>Cl has also beenreported to reduce the occurence of bladder tumours, where the mechanism is notthought to be urolith-mediated [<xref ref-type="bibr" rid="B107">120</xref>&#x02013;<xref ref-type="bibr" rid="B109">122</xref>], andNH<sub>4</sub>Cl feeding of rats can also influence the occurrence of tumoursoutside of the urinary bladder [<xref ref-type="bibr" rid="B110">123</xref>]. Infact, systemic acidosis induced by NH<sub>4</sub>Cl would be expected to haveprofound effects on cellular and organ function in the whole organism,including the bladder [<xref ref-type="bibr" rid="B110">123</xref>&#x02013;<xref ref-type="bibr" rid="B116">129</xref>]. Therefore, while some aspects of bladder function are unaffected by NH<sub>4</sub>Clfeeding [<xref ref-type="bibr" rid="B117">130</xref>], theimpact of systemic acidosis on bladder cancer development may be unrelated tourolith formation. Further, it is possible that induction of acidosis maydirectly interfere with the action of some PPAR agonists [<xref ref-type="bibr" rid="B118">131</xref>&#x02013;<xref ref-type="bibr" rid="B121">134</xref>]. Inshort, induction of systemic acidosismay not specifically discriminate between mechanisms of PPAR carcinogenicity inthe rat urothelium (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec sec-type="section" id="sec8"><title>8. CURRENT MECHANISM HYPOTHESIS FORUROTHELIAL CANCERS INDUCED BYDUAL-ACTING PPAR AGONISTS IN THE RAT</title><p>We have attempted to integrate the urothelial changesobserved in ragaglitazar-treated rats [<xref ref-type="bibr" rid="B11">28</xref>&#x02013;<xref ref-type="bibr" rid="B13">30</xref>],results from ragaglitazar-treated urothelial cell cultures [<xref ref-type="bibr" rid="B47">61</xref>],knowledge about PPARs in urothelial biology (see <xref ref-type="fig" rid="fig3">Figure 3</xref>), and new data aboutPPAR isoform expression in rat and human bladder [<xref ref-type="bibr" rid="B36">18</xref>] into amode of action hypothesis for urothelial carcinogenesis by dual-acting PPARagonsts in rat urothelium (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>The hypothesis is completely speculative (<xref ref-type="fig" rid="fig3">Figure 3</xref>), butto our knowledge, does not conflict with current knowledge of PPAR biology (see<xref ref-type="fig" rid="fig3">Figure 3</xref>). The main predictions of the hypothesis are that (i) coactivation of PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic>in the rat urothelium can produce effects different from those observed withspecific activation of either PPAR<italic>&#x003b1;</italic> or PPAR<italic>&#x003b3;</italic>, (ii) the effects of dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists on earlybiomarkers (e.g., Egr-1) depend on structural aspects such as PPAR selectivity,affinity, and activating effect of the agonist, and (iii) early biomarker changes (e.g., Egr-1 induction,phosphorylation of c-jun and S6) are causally involved in later urothelialcancer development.</p><p>For practical reasons, our focus is on early (precancerous) changes in the ratbladder urothelium (<xref ref-type="fig" rid="fig3">Figure 3</xref>), but involvement of PPARs in later stages ofurothelial cancer progression is also possible by paracrine [<xref ref-type="bibr" rid="B38">51</xref>] orimmunological mechanisms [<xref ref-type="bibr" rid="B19">35</xref>].</p></sec><sec sec-type="section" id="sec9"><title>9. FUTURE DIRECTIONS</title><p>In practical experimental terms, based on the mode ofaction hypothesis presented in <xref ref-type="fig" rid="fig3">Figure 3</xref>, we currently prioritize (i) evaluating cross-talk betweenPPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> signalling in urothelial cells, by treating rats orally withrosiglitazone and fenofibrate either separately or in combination with short-termstudies [<xref ref-type="bibr" rid="B11">28</xref>], (ii) evaluating the causal role ofEgr-1 in urothelial cancer development by, for example, chromatinimmunoprecipitation experiments from rat bladder, and (iii) comparing the findings between rat urothelium in vivo and finite cultures of normalrat and human urothelial cell in vitro.</p><p>Specifically, we believe that establishing cause-effectrelationships between early biomarkers and later cancer development is key tounderstand the mode of action for carcinogenic effects of dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic>agonists in the rat urothelium (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Validating early carcinogenicitybiomarkers in rats should also allow developing simple preclinical assays torank the carcinogenic potential of developmental PPAR agonists (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Additionally, understanding the mechanisms in rats (<xref ref-type="fig" rid="fig3">Figure 3</xref>) would aid inassessing the human relevance of the rat bladder cancer findings [<xref ref-type="bibr" rid="B122">135</xref>, <xref ref-type="bibr" rid="B123">136</xref>].</p><p>Finally, a recent study showed that the specific PPAR<italic>&#x003b3;</italic>agonist rosiglitazone is a strong promoter of hydroxybutyl(butyl)nitrosamine-inducedbladder cancer in rats [<xref ref-type="bibr" rid="B35">49</xref>]. It istempting, but obviously highly speculative, to integrate this obervation intothe proposed mode of action hypothesis for ragaglitazar-induced bladder cancersin rats (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The prediction would be that in the rat urothelium in vivo, PPAR<italic>&#x003b1;</italic> activation may providecancer initiation and PPAR<italic>&#x003b3;</italic> activation cancer promotion signals. A plausiblecancer initiation mechanism by PPAR<italic>&#x003b1;</italic> activation is peroxisome formation andfree radical production. Thus, exploring the effects of specific PPAR<italic>&#x003b1;</italic> agonistsin the rat urothelium would seem ahighly worthwhile  undertaking. 			</p></sec></body><back><glossary><title>NOMENCLATURE</title><def-list><def-item><term>Akt:</term><def><p>Protein kinase B</p></def></def-item><def-item><term>EGFR:</term><def><p>Epidermal growth factor receptor</p></def></def-item><def-item><term>Egr-1:</term><def><p>Zif268, early growth response protein 1, zinc finger transcription factor</p></def></def-item><def-item><term>FOXA1:</term><def><p>Forkhead box A1</p></def></def-item><def-item><term>HNF-3 alpha:</term><def><p>Hepatocyte nuclear factor-3 alpha, winged helix transcription factor</p></def></def-item><def-item><term>IRF-1:</term><def><p>Interferon regulatory factor 1</p></def></def-item><def-item><term>NHU:</term><def><p>Finite normal human urothelial cell lines</p></def></def-item><def-item><term>PPAR:</term><def><p>Peroxisome proliferator-activated receptor</p></def></def-item><def-item><term>PI3K:</term><def><p>Phosphatidyl inositol 3 kinase</p></def></def-item><def-item><term>S6:</term><def><p>Ribosomal protein.</p></def></def-item></def-list></glossary><ack><title>ACKNOWLEDGMENTS</title><p>Hanne Vikj&#x000e6;r Andersen is thanked for facilitating the rat experiments; Amanda J. Nicholl, Pettit, Bikramjit Chopra, and Niels Br&#x000fc;nner are thanked for helpfull discussions; Trine B. Cohn, Lis S. S&#x000f8;rensen, Ulla K. Thinggaard, and Linda E. Pedersen are thanked for help with animal experiments; J. Southgate is supported by York Against Cancer.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>JP</given-names></name><name><surname>Akiyama</surname><given-names>TE</given-names></name><name><surname>Meinke</surname><given-names>PT</given-names></name></person-group><article-title>PPARs: therapeutic targets for metabolic disease</article-title><source><italic>Trends in Pharmacological Sciences</italic></source><year>2005</year><volume>26</volume><issue>5</issue><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">15860371</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nahl&#x000e9;</surname><given-names>Z</given-names></name></person-group><article-title>PPAR trilogy from metabolism to cancer</article-title><source><italic>Current Opinion in Clinical Nutrition and Metabolic Care</italic></source><year>2004</year><volume>7</volume><issue>4</issue><fpage>397</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">15192441</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fi&#x000e9;vet</surname><given-names>C</given-names></name><name><surname>Fruchart</surname><given-names>J-C</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name></person-group><article-title>PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> dual agonists for the treatment of type 2 diabetes and the metabolic syndrome</article-title><source><italic>Current Opinion in Pharmacology</italic></source><year>2006</year><volume>6</volume><issue>6</issue><fpage>606</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">16973418</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balakumar</surname><given-names>P</given-names></name><name><surname>Rose</surname><given-names>M</given-names></name><name><surname>Ganti</surname><given-names>SS</given-names></name><name><surname>Krishan</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name></person-group><article-title>PPAR dual agonists: are they opening Pandora's Box?</article-title><source><italic>Pharmacological Research</italic></source><year>2007</year><volume>56</volume><issue>2</issue><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">17428674</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubenstrunk</surname><given-names>A</given-names></name><name><surname>Hanf</surname><given-names>R</given-names></name><name><surname>Hum</surname><given-names>DW</given-names></name><name><surname>Fruchart</surname><given-names>J-C</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name></person-group><article-title>Safety issues and prospects for future generations of PPAR modulators</article-title><source><italic>Biochimica et Biophysica Acta</italic></source><year>2007</year><volume>1771</volume><issue>8</issue><fpage>1065</fpage><lpage>1081</lpage><pub-id pub-id-type="pmid">17428730</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rumi</surname><given-names>MAK</given-names></name><name><surname>Ishihara</surname><given-names>S</given-names></name><name><surname>Kazumori</surname><given-names>H</given-names></name><name><surname>Kadowaki</surname><given-names>Y</given-names></name><name><surname>Kinoshita</surname><given-names>Y</given-names></name></person-group><article-title>Can PRAR<italic>&#x003b3;</italic> ligands be used in cancer therapy?</article-title><source><italic>Current Medicinal Chemistry. Anti-Cancer Agents</italic></source><year>2004</year><volume>4</volume><issue>6</issue><fpage>465</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">15579013</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conlon</surname><given-names>D</given-names></name></person-group><article-title>Goodbye glitazars?</article-title><source><italic>British Journal of Diabetes and Vascular Disease</italic></source><year>2006</year><volume>6</volume><issue>3</issue><fpage>135</fpage><lpage>137</lpage></citation></ref><ref id="B8"><label>8</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>El-Hage</surname><given-names>J</given-names></name></person-group><article-title>Preclinical and clinical safety assessments for PPAR agonists</article-title><comment>2004, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/cder/present/DIA2004/Elhage.ppt">http://www.fda.gov/cder/present/DIA2004/Elhage.ppt</ext-link></comment></citation></ref><ref id="B21"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peraza</surname><given-names>MA</given-names></name><name><surname>Burdick</surname><given-names>AD</given-names></name><name><surname>Marin</surname><given-names>HE</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Peters</surname><given-names>JM</given-names></name></person-group><article-title>The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR)</article-title><source><italic>Toxicological Sciences</italic></source><year>2006</year><volume>90</volume><issue>2</issue><fpage>269</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">16322072</pub-id></citation></ref><ref id="B124"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klaunig</surname><given-names>JE</given-names></name><name><surname>Babich</surname><given-names>MA</given-names></name><name><surname>Baetcke</surname><given-names>KP</given-names></name><etal/></person-group><article-title>PPAR<italic>&#x003b1;</italic> agonist-induced rodent tumors: modes of action and human relevance</article-title><source><italic>Critical Reviews in Toxicology</italic></source><year>2003</year><volume>33</volume><issue>6</issue><fpage>655</fpage><lpage>780</lpage><pub-id pub-id-type="pmid">14727734</pub-id></citation></ref><ref id="B9"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wulff</surname><given-names>EM</given-names></name><name><surname>Jeppesen</surname><given-names>L</given-names></name><name><surname>Bury</surname><given-names>PS</given-names></name><etal/></person-group><article-title>The anti-diabetic activity of the dual-acting PPAR<italic>&#x003b1;</italic>/<italic>&#x003b3;</italic> agonist ragaglitazar: a comparative study with known insulin sensitizers in vitro and in vivo</article-title><source><italic>Diabetologia</italic></source><year>2002</year><volume>45</volume><issue>supplement 2</issue><fpage>p. 727</fpage></citation></ref><ref id="B128"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohnishi</surname><given-names>T</given-names></name><name><surname>Arnold</surname><given-names>LL</given-names></name><name><surname>Clark</surname><given-names>NM</given-names></name><name><surname>Wisecarver</surname><given-names>JL</given-names></name><name><surname>Cohen</surname><given-names>SM</given-names></name></person-group><article-title>Comparison of endothelial cell proliferation in normal liver and adipose tissue in B6C3F1 mice, F344 rats, and humans</article-title><source><italic>Toxicologic Pathology</italic></source><year>2007</year><volume>35</volume><issue>7</issue><fpage>904</fpage><lpage>909</lpage><pub-id pub-id-type="pmid">18098037</pub-id></citation></ref><ref id="B15"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hellmold</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Andersson</surname><given-names>U</given-names></name><etal/></person-group><article-title>Tesaglitazar, a PPAR<italic>&#x003b1;</italic>/<italic>&#x003b3;</italic> agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats</article-title><source><italic>Toxicological Sciences</italic></source><year>2007</year><volume>98</volume><issue>1</issue><fpage>63</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">17468185</pub-id></citation></ref><ref id="B129"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>JR</given-names></name><name><surname>Dethloff</surname><given-names>LA</given-names></name><name><surname>McGuire</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone</article-title><source><italic>Toxicological Sciences</italic></source><year>2002</year><volume>68</volume><issue>1</issue><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">12075125</pub-id></citation></ref><ref id="B95"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Michalik</surname><given-names>L</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name><name><surname>Berger</surname><given-names>JP</given-names></name><etal/></person-group><article-title>International union of pharmacology. LXI. Peroxisome proliferator-activated receptors</article-title><source><italic>Pharmacological Reviews</italic></source><year>2006</year><volume>58</volume><issue>4</issue><fpage>726</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">17132851</pub-id></citation></ref><ref id="B130"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Escher</surname><given-names>P</given-names></name><name><surname>Braissant</surname><given-names>O</given-names></name><name><surname>Basu-Modak</surname><given-names>S</given-names></name><name><surname>Michalik</surname><given-names>L</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name><name><surname>Desvergne</surname><given-names>B</given-names></name></person-group><article-title>Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding</article-title><source><italic>Endocrinology</italic></source><year>2001</year><volume>142</volume><issue>10</issue><fpage>4195</fpage><lpage>4202</lpage><pub-id pub-id-type="pmid">11564675</pub-id></citation></ref><ref id="B24"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Davis</surname><given-names>L</given-names></name><name><surname>Breyer</surname><given-names>MD</given-names></name></person-group><article-title>Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans</article-title><source><italic>American Journal of Physiology</italic></source><year>1997</year><volume>273</volume><issue>6, part 2</issue><fpage>F1013</fpage><lpage>F1022</lpage><pub-id pub-id-type="pmid">9435691</pub-id></citation></ref><ref id="B36"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chopra</surname><given-names>B</given-names></name><name><surname>Hinley</surname><given-names>J</given-names></name><name><surname>Oleksiewicz</surname><given-names>MB</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name></person-group><article-title>Trans-species comparison of PPAR and RXR expression by rat and human urothelial tissues</article-title><source><italic>Toxicologic Pathology</italic></source><year>2008</year><volume>36</volume><issue>3</issue><fpage>485</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">18441255</pub-id></citation></ref><ref id="B42"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Ciuceis</surname><given-names>C</given-names></name><name><surname>Amiri</surname><given-names>F</given-names></name><name><surname>Iglarz</surname><given-names>M</given-names></name><name><surname>Cohn</surname><given-names>JS</given-names></name><name><surname>Touyz</surname><given-names>RM</given-names></name><name><surname>Schiffrin</surname><given-names>EL</given-names></name></person-group><article-title>Synergistic vascular protective effects of combined low doses of PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> activators in angiotensin II-induced hypertension in rats</article-title><source><italic>British Journal of Pharmacology</italic></source><year>2007</year><volume>151</volume><issue>1</issue><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">17351653</pub-id></citation></ref><ref id="B96"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Touyz</surname><given-names>RM</given-names></name><name><surname>Schiffrin</surname><given-names>EL</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications</article-title><source><italic>Vascular Pharmacology</italic></source><year>2006</year><volume>45</volume><issue>1</issue><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">16782410</pub-id></citation></ref><ref id="B131"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mazzucotelli</surname><given-names>A</given-names></name><name><surname>Viguerie</surname><given-names>N</given-names></name><name><surname>Tiraby</surname><given-names>C</given-names></name><etal/></person-group><article-title>The transcriptional coactivator peroxisome proliferator-activated receptor (PPAR)<italic>&#x003b3;</italic> coactivator-1<italic>&#x003b1;</italic> and the nuclear receptor PPAR<italic>&#x003b1;</italic> control the expression of glycerol kinase and metabolism genes independently of PPAR<italic>&#x003b3;</italic> activation in human white adipocytes</article-title><source><italic>Diabetes</italic></source><year>2007</year><volume>56</volume><issue>10</issue><fpage>2467</fpage><lpage>2475</lpage><pub-id pub-id-type="pmid">17646210</pub-id></citation></ref><ref id="B132"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vidal-Puig</surname><given-names>A</given-names></name><name><surname>Jimenez-Li&#x000f1;an</surname><given-names>M</given-names></name><name><surname>Lowell</surname><given-names>BB</given-names></name><etal/></person-group><article-title>Regulation of PPAR <italic>&#x003b3;</italic> gene expression by nutrition and obesity in rodents</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>1996</year><volume>97</volume><issue>11</issue><fpage>2553</fpage><lpage>2561</lpage><pub-id pub-id-type="pmid">8647948</pub-id></citation></ref><ref id="B133"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H-I</given-names></name><name><surname>Koh</surname><given-names>Y-K</given-names></name><name><surname>Kim</surname><given-names>T-H</given-names></name><etal/></person-group><article-title>Transcriptional activation of SHP by PPAR-<italic>&#x003b3;</italic> in liver</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2007</year><volume>360</volume><issue>2</issue><fpage>301</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">17601490</pub-id></citation></ref><ref id="B134"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viswakarma</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Naik</surname><given-names>S</given-names></name><etal/></person-group><article-title>Transcriptional regulation of Cidea, mitochondrial cell death-inducing DNA fragmentation factor <italic>&#x003b1;</italic>-like effector A, in mouse liver by peroxisome proliferator-activated receptor <italic>&#x003b1;</italic> and <italic>&#x003b3;</italic></article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2007</year><volume>282</volume><issue>25</issue><fpage>18613</fpage><lpage>18624</lpage><pub-id pub-id-type="pmid">17462989</pub-id></citation></ref><ref id="B135"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Sweeney</surname><given-names>TR</given-names></name><name><surname>Shigenaga</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Tumor necrosis factor and interleukin 1 decrease RXR<italic>&#x003b1;</italic>, PPAR<italic>&#x003b1;</italic>, PPAR<italic>&#x003b3;</italic>, LXR<italic>&#x003b1;</italic>, and the coactivators SRC-1, PGC-1<italic>&#x003b1;</italic>, and PGC-1<italic>&#x003b2;</italic> in liver cells</article-title><source><italic>Metabolism: Clinical and Experimental</italic></source><year>2007</year><volume>56</volume><issue>2</issue><fpage>267</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">17224343</pub-id></citation></ref><ref id="B136"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lanne</surname><given-names>B</given-names></name><name><surname>Dahll&#x000f6;f</surname><given-names>B</given-names></name><name><surname>Lindahl</surname><given-names>C</given-names></name><etal/></person-group><article-title>PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> regulation of liver and adipose proteins in obese and dyslipidemic rodents</article-title><source><italic>Journal of Proteome Research</italic></source><year>2006</year><volume>5</volume><issue>8</issue><fpage>1850</fpage><lpage>1859</lpage><pub-id pub-id-type="pmid">16889406</pub-id></citation></ref><ref id="B10"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waites</surname><given-names>CR</given-names></name><name><surname>Dominick</surname><given-names>MA</given-names></name><name><surname>Sanderson</surname><given-names>TP</given-names></name><name><surname>Schilling</surname><given-names>BE</given-names></name></person-group><article-title>Nonclinical safety evaluation of muraglitazar, a novel PPAR<italic>&#x003b1;</italic>/<italic>&#x003b3;</italic> agonist</article-title><source><italic>Toxicological Sciences</italic></source><year>2007</year><volume>100</volume><issue>1</issue><fpage>248</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">17675651</pub-id></citation></ref><ref id="B11"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egerod</surname><given-names>FL</given-names></name><name><surname>Nielsen</surname><given-names>HS</given-names></name><name><surname>Iversen</surname><given-names>L</given-names></name><name><surname>Thorup</surname><given-names>I</given-names></name><name><surname>Storgaard</surname><given-names>T</given-names></name><name><surname>Oleksiewicz</surname><given-names>MB</given-names></name></person-group><article-title>Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo</article-title><source><italic>Biomarkers</italic></source><year>2005</year><volume>10</volume><issue>4</issue><fpage>295</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">16240504</pub-id></citation></ref><ref id="B12"><label>29</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>BS</given-names></name><name><surname>Dominick</surname><given-names>M</given-names></name><name><surname>Iversen</surname><given-names>L</given-names></name><name><surname>Oleksiewicz</surname><given-names>MB</given-names></name></person-group><article-title>Peroxisome proliferators activated receptors (PPARs) agonists and rodent tumorigenesis: updating the discussions</article-title><conf-name>In: Proceedings of the 42nd DIA Annual Meeting</conf-name><conf-date>June 2006</conf-date><conf-loc>Philadelphia, Pa, USA</conf-loc><comment>BT Biotechnology/ NC Nonclinical Labaroratory Safety 299D</comment></citation></ref><ref id="B13"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oleksiewicz</surname><given-names>MB</given-names></name><name><surname>Thorup</surname><given-names>I</given-names></name><name><surname>Nielsen</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo</article-title><source><italic>Toxicologic Pathology</italic></source><year>2005</year><volume>33</volume><issue>5</issue><fpage>552</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">16076770</pub-id></citation></ref><ref id="B14"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>GG</given-names></name><name><surname>Reynolds</surname><given-names>VL</given-names></name><name><surname>Lopez-Martinez</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>TE</given-names></name><name><surname>White</surname><given-names>SL</given-names></name><name><surname>Eldridge</surname><given-names>SR</given-names></name></person-group><article-title>Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a <italic>&#x003b3;</italic>-dominant PPAR <italic>&#x003b1;</italic>/<italic>&#x003b3;</italic> agonist: lack of evidence for urolithiasis as an inciting event</article-title><source><italic>Toxicologic Pathology</italic></source><year>2008</year><volume>36</volume><issue>2</issue><fpage>218</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">18474944</pub-id></citation></ref><ref id="B16"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Shah</surname><given-names>YM</given-names></name></person-group><article-title>PPAR<italic>&#x003b1;</italic>: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators</article-title><source><italic>Toxicology</italic></source><year>2008</year><volume>246</volume><issue>1</issue><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18006136</pub-id></citation></ref><ref id="B17"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>YM</given-names></name><name><surname>Morimura</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Tanabe</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>M</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b1;</italic> regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation</article-title><source><italic>Molecular and Cellular Biology</italic></source><year>2007</year><volume>27</volume><issue>12</issue><fpage>4238</fpage><lpage>4247</lpage><pub-id pub-id-type="pmid">17438130</pub-id></citation></ref><ref id="B18"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panigrahy</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Kieran</surname><given-names>MW</given-names></name><name><surname>Kaipainen</surname><given-names>A</given-names></name></person-group><article-title>PPAR<italic>&#x003b3;</italic> as a therapeutic target for tumor angiogenesis and metastasis</article-title><source><italic>Cancer Biology and Therapy</italic></source><year>2005</year><volume>4</volume><issue>7</issue><fpage>687</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">16082179</pub-id></citation></ref><ref id="B19"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaipainen</surname><given-names>A</given-names></name><name><surname>Kieran</surname><given-names>MW</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><etal/></person-group><article-title>PPAR<italic>&#x003b1;</italic> deficiency in inflammatory cells suppresses tumor growth</article-title><source><italic>PLoS ONE</italic></source><year>2007</year><volume>2</volume><issue>2, article e260</issue><fpage>1</fpage><lpage>11</lpage></citation></ref><ref id="B20"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Agus</surname><given-names>DB</given-names></name></person-group><article-title>PPAR<italic>&#x003b3;</italic> signaling: one size fits all?</article-title><source><italic>Cell Cycle</italic></source><year>2004</year><volume>3</volume><issue>11</issue><fpage>1352</fpage><lpage>1354</lpage><pub-id pub-id-type="pmid">15467471</pub-id></citation></ref><ref id="B22"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keshamouni</surname><given-names>VG</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Roman</surname><given-names>J</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptors in lung cancer</article-title><source><italic>PPAR Research</italic></source><year>2007</year><volume>2007</volume><fpage>10 pages</fpage><comment>Article ID 90289.</comment></citation></ref><ref id="B23"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Pulikuri</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Differential expression of the peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> (PPAR<italic>&#x003b3;</italic>) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse</article-title><source><italic>American Journal of Pathology</italic></source><year>1998</year><volume>153</volume><issue>2</issue><fpage>349</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">9708794</pub-id></citation></ref><ref id="B25"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stahlschmidt</surname><given-names>J</given-names></name><name><surname>Varley</surname><given-names>CL</given-names></name><name><surname>Toogood</surname><given-names>G</given-names></name><name><surname>Selby</surname><given-names>PJ</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name></person-group><article-title>Urothelial differentiation in chronically urine-deprived bladders of patients with end-stage renal disease</article-title><source><italic>Kidney International</italic></source><year>2005</year><volume>68</volume><issue>3</issue><fpage>1032</fpage><lpage>1040</lpage><pub-id pub-id-type="pmid">16105033</pub-id></citation></ref><ref id="B26"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varley</surname><given-names>CL</given-names></name><name><surname>Stahlschmidt</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Stower</surname><given-names>M</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name></person-group><article-title>Activation of peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells</article-title><source><italic>American Journal of Pathology</italic></source><year>2004</year><volume>164</volume><issue>5</issue><fpage>1789</fpage><lpage>1798</lpage><pub-id pub-id-type="pmid">15111325</pub-id></citation></ref><ref id="B27"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakashiro</surname><given-names>K-I</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><name><surname>Kita</surname><given-names>A</given-names></name><etal/></person-group><article-title>Role of peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> and its ligands in non-neoplastic and neoplastic human urothelial cells</article-title><source><italic>American Journal of Pathology</italic></source><year>2001</year><volume>159</volume><issue>2</issue><fpage>591</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">11485917</pub-id></citation></ref><ref id="B28"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Southgate</surname><given-names>J</given-names></name><name><surname>Hutton</surname><given-names>KA</given-names></name><name><surname>Thomas</surname><given-names>DF</given-names></name><name><surname>Trejdosiewicz</surname><given-names>LK</given-names></name></person-group><article-title>Normal human urothelial cells in vitro: proliferation and induction of stratification</article-title><source><italic>Laboratory Investigation</italic></source><year>1994</year><volume>71</volume><issue>4</issue><fpage>583</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">7967513</pub-id></citation></ref><ref id="B29"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crallan</surname><given-names>RA</given-names></name><name><surname>Georgopoulos</surname><given-names>NT</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name></person-group><article-title>Experimental models of human bladder carcinogenesis</article-title><source><italic>Carcinogenesis</italic></source><year>2006</year><volume>27</volume><issue>3</issue><fpage>374</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">16287878</pub-id></citation></ref><ref id="B30"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varley</surname><given-names>CL</given-names></name><name><surname>Stahlschmidt</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>W-C</given-names></name><etal/></person-group><article-title>Role of PPAR <italic>&#x003b3;</italic> and EGFR signalling in the urothelial terminal differentiation programme</article-title><source><italic>Journal of Cell Science</italic></source><year>2004</year><volume>117</volume><issue>10</issue><fpage>2029</fpage><lpage>2036</lpage><pub-id pub-id-type="pmid">15054105</pub-id></citation></ref><ref id="B31"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varley</surname><given-names>CL</given-names></name><name><surname>Garthwaite</surname><given-names>MAE</given-names></name><name><surname>Cross</surname><given-names>W</given-names></name><name><surname>Hinley</surname><given-names>J</given-names></name><name><surname>Trejdosiewicz</surname><given-names>LK</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name></person-group><article-title>PPAR<italic>&#x003b3;</italic>-regulated tight junction development during human urothelial cytodifferentiation</article-title><source><italic>Journal of Cellular Physiology</italic></source><year>2006</year><volume>208</volume><issue>2</issue><fpage>407</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">16688762</pub-id></citation></ref><ref id="B32"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varley</surname><given-names>CL</given-names></name><name><surname>Bacon</surname><given-names>EJ</given-names></name><name><surname>Holder</surname><given-names>JC</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name></person-group><article-title>FOXA1 and IRF-1 intermediary transcriptional regulators of PPAR<italic>&#x003b3;</italic>-induced urothelial cytodifferentiation</article-title><source><italic>Cell Death &#x00026; Differentiation</italic></source><year>2008</year><volume>16</volume><issue>1</issue><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">18688264</pub-id></citation></ref><ref id="B33"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varley</surname><given-names>C</given-names></name><name><surname>Hill</surname><given-names>G</given-names></name><name><surname>Pellegrin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro</article-title><source><italic>Experimental Cell Research</italic></source><year>2005</year><volume>306</volume><issue>1</issue><fpage>216</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">15878346</pub-id></citation></ref><ref id="B34"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>SM</given-names></name></person-group><article-title>Effects of PPAR<italic>&#x003b3;</italic> and combined agonists on the urinary tract of rats and other species</article-title><source><italic>Toxicological Sciences</italic></source><year>2005</year><volume>87</volume><issue>2</issue><fpage>322</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">16049269</pub-id></citation></ref><ref id="B35"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lubet</surname><given-names>RA</given-names></name><name><surname>Fischer</surname><given-names>SM</given-names></name><name><surname>Steele</surname><given-names>VE</given-names></name><name><surname>Juliana</surname><given-names>MM</given-names></name><name><surname>Desmond</surname><given-names>R</given-names></name><name><surname>Grubbs</surname><given-names>CJ</given-names></name></person-group><article-title>Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers</article-title><source><italic>International Journal of Cancer</italic></source><year>2008</year><volume>123</volume><issue>10</issue><fpage>2254</fpage><lpage>2259</lpage></citation></ref><ref id="B37"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutton</surname><given-names>KA</given-names></name><name><surname>Trejdosiewicz</surname><given-names>LK</given-names></name><name><surname>Thomas</surname><given-names>DF</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name></person-group><article-title>Urothelial tissue culture for bladder reconstruction: an experimental study</article-title><source><italic>The Journal of Urology</italic></source><year>1993</year><volume>150</volume><issue>2, part 2</issue><fpage>721</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">8326633</pub-id></citation></ref><ref id="B38"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fauconnet</surname><given-names>S</given-names></name><name><surname>Lascombe</surname><given-names>I</given-names></name><name><surname>Chabannes</surname><given-names>E</given-names></name><etal/></person-group><article-title>Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2002</year><volume>277</volume><issue>26</issue><fpage>23534</fpage><lpage>23543</lpage><pub-id pub-id-type="pmid">11980898</pub-id></citation></ref><ref id="B39"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hagiwara</surname><given-names>A</given-names></name><name><surname>Tamano</surname><given-names>S</given-names></name><name><surname>Ogiso</surname><given-names>T</given-names></name><name><surname>Asakawa</surname><given-names>E</given-names></name><name><surname>Fukushima</surname><given-names>S</given-names></name></person-group><article-title>Promoting effect of the peroxisome proliferator, clofibrate, but not di(2-ethylhexyl)phthalate, on urinary bladder carcinogenesis in F344 rats initiated by <italic>N</italic>-butyl-<italic>N</italic>-(4-hydroxybutyl)nitrosamine</article-title><source><italic>Japanese Journal of Cancer Research</italic></source><year>1990</year><volume>81</volume><issue>12</issue><fpage>1232</fpage><lpage>1238</lpage><pub-id pub-id-type="pmid">2125992</pub-id></citation></ref><ref id="B40"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Morris</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity</article-title><source><italic>Oncogene</italic></source><year>2006</year><volume>25</volume><issue>8</issue><fpage>1225</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">16288226</pub-id></citation></ref><ref id="B41"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mensink</surname><given-names>M</given-names></name><name><surname>Hesselink</surname><given-names>MKC</given-names></name><name><surname>Russell</surname><given-names>AP</given-names></name><name><surname>Schaart</surname><given-names>G</given-names></name><name><surname>Sels</surname><given-names>J-P</given-names></name><name><surname>Schrauwen</surname><given-names>P</given-names></name></person-group><article-title>Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1<italic>&#x003b1;</italic> and PPAR<italic>&#x003b2;</italic>/<italic>&#x003b4;</italic> gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus</article-title><source><italic>International Journal of Obesity</italic></source><year>2007</year><volume>31</volume><issue>8</issue><fpage>1302</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">17310221</pub-id></citation></ref><ref id="B43"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>M</given-names></name><name><surname>Balakumar</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name></person-group><article-title>Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats</article-title><source><italic>Pharmacology</italic></source><year>2007</year><volume>80</volume><issue>2-3</issue><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">17570955</pub-id></citation></ref><ref id="B44"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lohray</surname><given-names>BB</given-names></name><name><surname>Lohray</surname><given-names>VB</given-names></name><name><surname>Bajji</surname><given-names>AC</given-names></name><etal/></person-group><article-title>(-)3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity</article-title><source><italic>Journal of Medicinal Chemistry</italic></source><year>2001</year><volume>44</volume><issue>16</issue><fpage>2675</fpage><lpage>2678</lpage><pub-id pub-id-type="pmid">11472221</pub-id></citation></ref><ref id="B45"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebdrup</surname><given-names>S</given-names></name><name><surname>Pettersson</surname><given-names>I</given-names></name><name><surname>Rasmussen</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor <italic>&#x003b1;</italic>/<italic>&#x003b3;</italic> agonist ragaglitazar</article-title><source><italic>Journal of Medicinal Chemistry</italic></source><year>2003</year><volume>46</volume><issue>8</issue><fpage>1306</fpage><lpage>1317</lpage><pub-id pub-id-type="pmid">12672231</pub-id></citation></ref><ref id="B61"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>JA</given-names></name><name><surname>Perera</surname><given-names>AD</given-names></name><name><surname>Walker</surname><given-names>CL</given-names></name></person-group><article-title>Mechanisms of epithelial development and neoplasia in the metanephric kidney</article-title><source><italic>International Journal of Developmental Biology</italic></source><year>1999</year><volume>43</volume><issue>5</issue><fpage>473</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">10535327</pub-id></citation></ref><ref id="B138"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riedel</surname><given-names>I</given-names></name><name><surname>Liang</surname><given-names>F-X</given-names></name><name><surname>Deng</surname><given-names>F-M</given-names></name><etal/></person-group><article-title>Urothelial umbrella cells of human ureter are heterogeneous with respect to their uroplakin composition: different degrees of urothelial maturity in ureter and bladder?</article-title><source><italic>European Journal of Cell Biology</italic></source><year>2005</year><volume>84</volume><issue>2-3</issue><fpage>393</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">15819416</pub-id></citation></ref><ref id="B46"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jhamb</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Ballow</surname><given-names>R</given-names></name><name><surname>Kamat</surname><given-names>AM</given-names></name><name><surname>Grossman</surname><given-names>HB</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>Urinary tract diseases and bladder cancer risk: a case-control study</article-title><source><italic>Cancer Causes &#x00026; Control</italic></source><year>2007</year><volume>18</volume><issue>8</issue><fpage>839</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">17593531</pub-id></citation></ref><ref id="B47"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chopra</surname><given-names>B</given-names></name><name><surname>Georgopoulos</surname><given-names>NT</given-names></name><name><surname>Nicholl</surname><given-names>A</given-names></name><name><surname>Hinley</surname><given-names>J</given-names></name><name><surname>Oleksiewicz</surname><given-names>MB</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name></person-group><article-title>Non-genomic cytotoxicity of structurally diverse PPAR agonists in normal human urothelial cells in vitro</article-title><comment>accepted, 2009, Cell Proliferation</comment></citation></ref><ref id="B48"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>OS</given-names></name><name><surname>Dewar</surname><given-names>BJ</given-names></name><name><surname>Graves</surname><given-names>LM</given-names></name></person-group><article-title>Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling</article-title><source><italic>Molecular Pharmacology</italic></source><year>2005</year><volume>68</volume><issue>4</issue><fpage>933</fpage><lpage>941</lpage><pub-id pub-id-type="pmid">16020742</pub-id></citation></ref><ref id="B49"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Croy</surname><given-names>RG</given-names></name></person-group><article-title>Role of chemically induced cell proliferation in carcinogenesis and its use in health risk assessment</article-title><source><italic>Environmental Health Perspectives</italic></source><year>1993</year><volume>101</volume><issue>supplement 5</issue><fpage>289</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">8013422</pub-id></citation></ref><ref id="B50"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomatis</surname><given-names>L</given-names></name></person-group><article-title>Cell proliferation and carcinogenesis: a brief history and current view based on an IARC workshop report</article-title><source><italic>Environmental Health Perspectives</italic></source><year>1993</year><volume>101</volume><issue>supplement 5</issue><fpage>149</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">8013403</pub-id></citation></ref><ref id="B51"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hartl</surname><given-names>M</given-names></name><name><surname>Bader</surname><given-names>AG</given-names></name><name><surname>Bister</surname><given-names>K</given-names></name></person-group><article-title>Molecular targets of the oncogenic transcription factor jun</article-title><source><italic>Current Cancer Drug Targets</italic></source><year>2003</year><volume>3</volume><issue>1</issue><fpage>41</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">12570660</pub-id></citation></ref><ref id="B52"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luster</surname><given-names>MI</given-names></name><name><surname>Simeonova</surname><given-names>PP</given-names></name></person-group><article-title>Arsenic and urinary bladder cell proliferation</article-title><source><italic>Toxicology and Applied Pharmacology</italic></source><year>2004</year><volume>198</volume><issue>3</issue><fpage>419</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">15276422</pub-id></citation></ref><ref id="B53"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simeonova</surname><given-names>PP</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Toriuma</surname><given-names>W</given-names></name><etal/></person-group><article-title>Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation</article-title><source><italic>Cancer Research</italic></source><year>2000</year><volume>60</volume><issue>13</issue><fpage>3445</fpage><lpage>3453</lpage><pub-id pub-id-type="pmid">10910055</pub-id></citation></ref><ref id="B54"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thiel</surname><given-names>G</given-names></name><name><surname>Cibelli</surname><given-names>G</given-names></name></person-group><article-title>Regulation of life and death by the zinc finger transcription factor Egr-1</article-title><source><italic>Journal of Cellular Physiology</italic></source><year>2002</year><volume>193</volume><issue>3</issue><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">12384981</pub-id></citation></ref><ref id="B55"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khachigian</surname><given-names>LM</given-names></name></person-group><article-title>Early growth response-1: blocking angiogenesis by shooting the messenger</article-title><source><italic>Cell Cycle</italic></source><year>2004</year><volume>3</volume><issue>1</issue><fpage>10</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">14657654</pub-id></citation></ref><ref id="B56"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levkovitz</surname><given-names>Y</given-names></name><name><surname>Baraban</surname><given-names>JM</given-names></name></person-group><article-title>A dominant negative Egr inhibitor blocks nerve growth factor-induced neurite outgrowth by suppressing c-Jun activation: role of an Egr/c-Jun complex</article-title><source><italic>Journal of Neuroscience</italic></source><year>2002</year><volume>22</volume><issue>10</issue><fpage>3845</fpage><lpage>3854</lpage><pub-id pub-id-type="pmid">12019303</pub-id></citation></ref><ref id="B57"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SL</given-names></name><name><surname>Sadovsky</surname><given-names>Y</given-names></name><name><surname>Swirnoff</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1)</article-title><source><italic>Science</italic></source><year>1996</year><volume>273</volume><issue>5279</issue><fpage>1219</fpage><lpage>1221</lpage><pub-id pub-id-type="pmid">8703054</pub-id></citation></ref><ref id="B58"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rauscher</surname><given-names>FJ</given-names><suffix>III</suffix></name><name><surname>Morris</surname><given-names>JF</given-names></name><name><surname>Tournay</surname><given-names>OE</given-names></name><name><surname>Cook</surname><given-names>DM</given-names></name><name><surname>Curran</surname><given-names>T</given-names></name></person-group><article-title>Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence</article-title><source><italic>Science</italic></source><year>1990</year><volume>250</volume><issue>4985</issue><fpage>1259</fpage><lpage>1262</lpage><pub-id pub-id-type="pmid">2244209</pub-id></citation></ref><ref id="B59"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghanem</surname><given-names>MA</given-names></name><name><surname>van der Kwast</surname><given-names>TH</given-names></name><name><surname>Den Hollander</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma</article-title><source><italic>Clinical Cancer Research</italic></source><year>2000</year><volume>6</volume><issue>11</issue><fpage>4265</fpage><lpage>4271</lpage><pub-id pub-id-type="pmid">11106242</pub-id></citation></ref><ref id="B60"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scharnhorst</surname><given-names>V</given-names></name><name><surname>Menke</surname><given-names>AL</given-names></name><name><surname>Attema</surname><given-names>J</given-names></name><etal/></person-group><article-title>EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity</article-title><source><italic>Oncogene</italic></source><year>2000</year><volume>19</volume><issue>6</issue><fpage>791</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">10698497</pub-id></citation></ref><ref id="B62"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rackley</surname><given-names>RR</given-names></name><name><surname>Kessler</surname><given-names>PM</given-names></name><name><surname>Campbell</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>BRG</given-names></name></person-group><article-title>In situ expression of the early growth response gene-1 during murine nephrogenesis</article-title><source><italic>The Journal of Urology</italic></source><year>1995</year><volume>154</volume><issue>2</issue><fpage>700</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">7609158</pub-id></citation></ref><ref id="B63"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>DM</given-names></name></person-group><article-title>Urea-inducible Egr-1 transcription in renal inner medullary collecting duct (mIMCD3) cells is mediated by extracellular signal-regulated kinase activation</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1996</year><volume>93</volume><issue>20</issue><fpage>11242</fpage><lpage>11247</lpage><pub-id pub-id-type="pmid">8855340</pub-id></citation></ref><ref id="B64"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saban</surname><given-names>MR</given-names></name><name><surname>Hellmich</surname><given-names>H</given-names></name><name><surname>Nguyen</surname><given-names>NB</given-names></name><name><surname>Winston</surname><given-names>J</given-names></name><name><surname>Hammond</surname><given-names>TG</given-names></name><name><surname>Saban</surname><given-names>R</given-names></name></person-group><article-title>Time course of LPS-induced gene expression in a mouse model of genitourinary inflammation</article-title><source><italic>Physiol Genomics</italic></source><year>2001</year><volume>5</volume><issue>3</issue><fpage>147</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">11285368</pub-id></citation></ref><ref id="B65"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saban</surname><given-names>R</given-names></name><name><surname>Simpson</surname><given-names>C</given-names></name><name><surname>Vadigepalli</surname><given-names>R</given-names></name><name><surname>Memet</surname><given-names>S</given-names></name><name><surname>Dozmorov</surname><given-names>I</given-names></name><name><surname>Saban</surname><given-names>MR</given-names></name></person-group><article-title>Bladder inflammatory transcriptome in response to tachykinins: neurokinin 1 receptor-dependent genes and transcription regulatory elements</article-title><source><italic>BMC Urology</italic></source><year>2007</year><volume>7, article 7</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">17244372</pub-id></citation></ref><ref id="B66"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Howard</surname><given-names>PS</given-names></name><name><surname>Kogan</surname><given-names>B</given-names></name><name><surname>Macarak</surname><given-names>EJ</given-names></name></person-group><article-title>Altered extracellular matrix expression in the diverted fetal sheep bladder</article-title><source><italic>The Journal of Urology</italic></source><year>2007</year><volume>178</volume><issue>3</issue><fpage>1104</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">17644133</pub-id></citation></ref><ref id="B67"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Kawakami</surname><given-names>S</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Spatial and isoform specific p63 expression in the male human urogenital tract</article-title><source><italic>The Journal of Urology</italic></source><year>2006</year><volume>176</volume><issue>5</issue><fpage>2268</fpage><lpage>2273</lpage><pub-id pub-id-type="pmid">17070310</pub-id></citation></ref><ref id="B68"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Pires</surname><given-names>MM</given-names></name><name><surname>Lindauer</surname><given-names>M</given-names></name><etal/></person-group><article-title>p63 regulates commitment to the prostate cell lineage</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2005</year><volume>102</volume><issue>32</issue><fpage>11355</fpage><lpage>11360</lpage><pub-id pub-id-type="pmid">16051706</pub-id></citation></ref><ref id="B69"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdulkadir</surname><given-names>SA</given-names></name></person-group><article-title>Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1</article-title><source><italic>Annals of the New York Academy of Sciences</italic></source><year>2005</year><volume>1059</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16382041</pub-id></citation></ref><ref id="B70"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdulkadir</surname><given-names>SA</given-names></name><name><surname>Qu</surname><given-names>Z</given-names></name><name><surname>Garabedian</surname><given-names>E</given-names></name><etal/></person-group><article-title>Impaired prostate tumorigenesis in Egr1-deficient mice</article-title><source><italic>Nature Medicine</italic></source><year>2001</year><volume>7</volume><issue>1</issue><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">11135623</pub-id></citation></ref><ref id="B71"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salah</surname><given-names>Z</given-names></name><name><surname>Maoz</surname><given-names>M</given-names></name><name><surname>Pizov</surname><given-names>G</given-names></name><name><surname>Bar-Shavit</surname><given-names>R</given-names></name></person-group><article-title>Transcriptional regulation of human <italic>protease-activated receptor</italic> 1: a role for the early growth response-1 protein in prostate cancer</article-title><source><italic>Cancer Research</italic></source><year>2007</year><volume>67</volume><issue>20</issue><fpage>9835</fpage><lpage>9843</lpage><pub-id pub-id-type="pmid">17942914</pub-id></citation></ref><ref id="B72"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Le</surname><given-names>T-S</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Konety</surname><given-names>BR</given-names></name><name><surname>Barder</surname><given-names>T</given-names></name><name><surname>Getzenberg</surname><given-names>RH</given-names></name></person-group><article-title>Functional characterization of the bladder cancer marker, BLCA-4</article-title><source><italic>Clinical Cancer Research</italic></source><year>2004</year><volume>10</volume><issue>4</issue><fpage>1384</fpage><lpage>1391</lpage><pub-id pub-id-type="pmid">14977841</pub-id></citation></ref><ref id="B73"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>ME</given-names></name><name><surname>Gonzalgo</surname><given-names>ML</given-names></name><name><surname>Schoenberg</surname><given-names>MP</given-names></name><name><surname>Getzenberg</surname><given-names>RH</given-names></name></person-group><article-title>Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer</article-title><source><italic>World Journal of Urology</italic></source><year>2006</year><volume>24</volume><issue>5</issue><fpage>499</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">17102951</pub-id></citation></ref><ref id="B74"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faridi</surname><given-names>J</given-names></name><name><surname>Fawcett</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Roth</surname><given-names>RA</given-names></name></person-group><article-title>Akt promotes increased mammalian cell size by stimulating protein synthesis and inhibiting protein degradation</article-title><source><italic>American Journal of Physiology</italic></source><year>2003</year><volume>285</volume><issue>5</issue><fpage>E964</fpage><lpage>E972</lpage><pub-id pub-id-type="pmid">12876075</pub-id></citation></ref><ref id="B75"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>EC</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name></person-group><article-title>Signaling control of mRNA translation in cancer pathogenesis</article-title><source><italic>Oncogene</italic></source><year>2004</year><volume>23</volume><issue>18</issue><fpage>3138</fpage><lpage>3144</lpage><pub-id pub-id-type="pmid">15094763</pub-id></citation></ref><ref id="B76"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>EC</given-names></name></person-group><article-title>Regulation of translation and cancer</article-title><source><italic>Cell Cycle</italic></source><year>2004</year><volume>3</volume><issue>4</issue><fpage>452</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">14976427</pub-id></citation></ref><ref id="B77"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petroulakis</surname><given-names>E</given-names></name><name><surname>Mamane</surname><given-names>Y</given-names></name><name><surname>Le Bacquer</surname><given-names>O</given-names></name><name><surname>Shahbazian</surname><given-names>D</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><article-title>mTOR signaling: implications for cancer and anticancer therapy</article-title><source><italic>British Journal of Cancer</italic></source><year>2006</year><volume>94</volume><issue>2</issue><fpage>195</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">16404421</pub-id></citation></ref><ref id="B78"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montagne</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>MJ</given-names></name><name><surname>Stocker</surname><given-names>H</given-names></name><name><surname>Hafen</surname><given-names>E</given-names></name><name><surname>Kozma</surname><given-names>SC</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name></person-group><article-title>						<italic>Drosophila</italic> S6 kinase: a regulator of cell size</article-title><source><italic>Science</italic></source><year>1999</year><volume>285</volume><issue>5436</issue><fpage>2126</fpage><lpage>2129</lpage><pub-id pub-id-type="pmid">10497130</pub-id></citation></ref><ref id="B79"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shima</surname><given-names>H</given-names></name><name><surname>Pende</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Fumagalli</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Kozma</surname><given-names>SC</given-names></name></person-group><article-title>Disruption of the p705<sup>s6k</sup>/p85<sup>s6k</sup> gene reveals a small mouse phenotype and a new functional S6 kinase</article-title><source><italic>The EMBO Journal</italic></source><year>1998</year><volume>17</volume><issue>22</issue><fpage>6649</fpage><lpage>6659</lpage><pub-id pub-id-type="pmid">9822608</pub-id></citation></ref><ref id="B80"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>AG</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Vogt</surname><given-names>PK</given-names></name></person-group><article-title>Oncogenic PI3K deregulates transcription and translation</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2005</year><volume>5</volume><issue>12</issue><fpage>921</fpage><lpage>929</lpage><pub-id pub-id-type="pmid">16341083</pub-id></citation></ref><ref id="B81"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Molon-Noblot</surname><given-names>S</given-names></name><name><surname>Boussiquet-Leroux</surname><given-names>C</given-names></name><name><surname>Owen</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Rat urinary bladder hyperplasia induced by oral administration of carbonic anhydrase inhibitors</article-title><source><italic>Toxicologic Pathology</italic></source><year>1992</year><volume>20</volume><issue>1</issue><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">1411136</pub-id></citation></ref><ref id="B82"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>TA</given-names></name><name><surname>Dawson</surname><given-names>KM</given-names></name><name><surname>Clayson</surname><given-names>DB</given-names></name></person-group><article-title>Acute changes in nucleic acid and protein synthesis in the mouse bladder epithelium induced by three bladder carcinogens</article-title><source><italic>Cancer Research</italic></source><year>1970</year><volume>30</volume><issue>6</issue><fpage>1586</fpage><lpage>1592</lpage><pub-id pub-id-type="pmid">5457932</pub-id></citation></ref><ref id="B83"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fingar</surname><given-names>DC</given-names></name><name><surname>Blenis</surname><given-names>J</given-names></name></person-group><article-title>Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression</article-title><source><italic>Oncogene</italic></source><year>2004</year><volume>23</volume><issue>18</issue><fpage>3151</fpage><lpage>3171</lpage><pub-id pub-id-type="pmid">15094765</pub-id></citation></ref><ref id="B84"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>OS</given-names></name><name><surname>Shiau</surname><given-names>C-W</given-names></name><name><surname>Chen</surname><given-names>C-S</given-names></name><name><surname>Graves</surname><given-names>LM</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b3;</italic>-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2005</year><volume>280</volume><issue>11</issue><fpage>10109</fpage><lpage>10118</lpage><pub-id pub-id-type="pmid">15649892</pub-id></citation></ref><ref id="B85"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dewar</surname><given-names>BJ</given-names></name><name><surname>Gardner</surname><given-names>OS</given-names></name><name><surname>Chen</surname><given-names>C-S</given-names></name><name><surname>Earp</surname><given-names>HS</given-names></name><name><surname>Samet</surname><given-names>JM</given-names></name><name><surname>Graves</surname><given-names>LM</given-names></name></person-group><article-title>Capacitative calcium entry contributes to the differential transactivation of the epidermal growth factor receptor in response to thiazolidinediones</article-title><source><italic>Molecular Pharmacology</italic></source><year>2007</year><volume>72</volume><issue>5</issue><fpage>1146</fpage><lpage>1156</lpage><pub-id pub-id-type="pmid">17686966</pub-id></citation></ref><ref id="B86"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f6;sel</surname><given-names>R</given-names></name><name><surname>Wehling</surname><given-names>M</given-names></name></person-group><article-title>Nongenomic actions of steroid hormones</article-title><source><italic>Nature Reviews Molecular Cell Biology</italic></source><year>2003</year><volume>4</volume><issue>1</issue><fpage>46</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">12511868</pub-id></citation></ref><ref id="B87"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>IK</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Seo</surname><given-names>JH</given-names></name></person-group><article-title>PPAR-<italic>&#x003b3;</italic> ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo</article-title><source><italic>Investigational New Drugs</italic></source><year>2008</year><volume>26</volume><issue>3</issue><fpage>283</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">18161004</pub-id></citation></ref><ref id="B88"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lucarelli</surname><given-names>E</given-names></name><name><surname>Sangiorgi</surname><given-names>L</given-names></name><name><surname>Maini</surname><given-names>V</given-names></name><etal/></person-group><article-title>Troglitazione affects survival of human osteosarcoma cells</article-title><source><italic>International Journal of Cancer</italic></source><year>2002</year><volume>98</volume><issue>3</issue><fpage>344</fpage><lpage>351</lpage></citation></ref><ref id="B89"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YL</given-names></name><name><surname>Frauwirth</surname><given-names>KA</given-names></name><name><surname>Rangwala</surname><given-names>SM</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><article-title>Thiazolidinedione activation of peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> can enhance mitochondrial potential and promote cell survival</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2002</year><volume>277</volume><issue>35</issue><fpage>31781</fpage><lpage>31788</lpage><pub-id pub-id-type="pmid">12082115</pub-id></citation></ref><ref id="B90"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clay</surname><given-names>CE</given-names></name><name><surname>Namen</surname><given-names>AM</given-names></name><name><surname>Atsumi</surname><given-names>G-I</given-names></name><etal/></person-group><article-title>Magnitude of peroxisome proliferator-activated receptor-<italic>&#x003b3;</italic> activation is associated with important and seemingly opposite biological responses in breast cancer cells</article-title><source><italic>Journal of Investigative Medicine</italic></source><year>2001</year><volume>49</volume><issue>5</issue><fpage>413</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">11523697</pub-id></citation></ref><ref id="B91"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>PA</given-names></name><name><surname>Varley</surname><given-names>CL</given-names></name><name><surname>Holder</surname><given-names>JC</given-names></name><name><surname>Cairns</surname><given-names>WJ</given-names></name><name><surname>Southgate</surname><given-names>J</given-names></name></person-group><article-title>Cytostasis of normal human urothelial  cell lines by PPARgamma agonists is independent of PPARgamma activation</article-title><comment>in preparation</comment></citation></ref><ref id="B92"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Southgate</surname><given-names>J</given-names></name><name><surname>Pitt</surname><given-names>E</given-names></name><name><surname>Trejdosiewicz</surname><given-names>LK</given-names></name></person-group><article-title>The effects of dietary fatty acids on the proliferation of normal human urothelial cells in vitro</article-title><source><italic>British Journal of Cancer</italic></source><year>1996</year><volume>74</volume><issue>5</issue><fpage>728</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">8795575</pub-id></citation></ref><ref id="B127"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abumrad</surname><given-names>NA</given-names></name></person-group><article-title>The PPAR balancing act</article-title><source><italic>Current Opinion in Clinical Nutrition and Metabolic Care</italic></source><year>2004</year><volume>7</volume><issue>4</issue><fpage>367</fpage><lpage>368</lpage></citation></ref><ref id="B144"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grommes</surname><given-names>C</given-names></name><name><surname>Landreth</surname><given-names>GE</given-names></name><name><surname>Heneka</surname><given-names>MT</given-names></name></person-group><article-title>Antineoplastic effects of peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> agonists</article-title><source><italic>The Lancet Oncology</italic></source><year>2004</year><volume>5</volume><issue>7</issue><fpage>419</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">15231248</pub-id></citation></ref><ref id="B97"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattern</surname><given-names>HM</given-names></name><name><surname>Lloyd</surname><given-names>PG</given-names></name><name><surname>Sturek</surname><given-names>M</given-names></name><name><surname>Hardin</surname><given-names>CD</given-names></name></person-group><article-title>Gender and genetic differences in bladder smooth muscle PPAR mRNA in a porcine model of the metabolic syndrome</article-title><source><italic>Molecular and Cellular Biochemistry</italic></source><year>2007</year><volume>302</volume><issue>1-2</issue><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">17318406</pub-id></citation></ref><ref id="B98"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Klaassen</surname><given-names>C</given-names></name></person-group><article-title>Gender differences in renal nuclear receptors and aryl hydrocarbon receptor in 5/6 nephrectomized rats</article-title><source><italic>Kidney International</italic></source><year>2006</year><volume>70</volume><issue>11</issue><fpage>1920</fpage><lpage>1928</lpage><pub-id pub-id-type="pmid">16985511</pub-id></citation></ref><ref id="B99"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanguino</surname><given-names>E</given-names></name><name><surname>Bejarano</surname><given-names>R</given-names></name><name><surname>Alegret</surname><given-names>M</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>RM</given-names></name><name><surname>V&#x000e1;zquez-Carrera</surname><given-names>M</given-names></name><name><surname>Laguna</surname><given-names>JC</given-names></name></person-group><article-title>Sexual dimorphism in lipid metabolic phenotype associated with old age in Sprague-Dawley rats</article-title><source><italic>Experimental Gerontology</italic></source><year>2004</year><volume>39</volume><issue>9</issue><fpage>1295</fpage><lpage>1306</lpage><pub-id pub-id-type="pmid">15489052</pub-id></citation></ref><ref id="B100"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez</surname><given-names>E</given-names></name><name><surname>Ribot</surname><given-names>J</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>AM</given-names></name><name><surname>Palou</surname><given-names>A</given-names></name></person-group><article-title>PPAR-<italic>&#x003b3;</italic>2 expression in response to cafeteria diet: gender- and depot-specific effects</article-title><source><italic>Obesity Research</italic></source><year>2004</year><volume>12</volume><issue>9</issue><fpage>1455</fpage><lpage>1463</lpage><pub-id pub-id-type="pmid">15483210</pub-id></citation></ref><ref id="B101"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jalouli</surname><given-names>M</given-names></name><name><surname>Carlsson</surname><given-names>L</given-names></name><name><surname>Am&#x000e9;en</surname><given-names>C</given-names></name><etal/></person-group><article-title>Sex difference in hepatic peroxisome proliferator-activated receptor <italic>&#x003b1;</italic> expression: influence of pituitary and gonadal hormones</article-title><source><italic>Endocrinology</italic></source><year>2003</year><volume>144</volume><issue>1</issue><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">12488335</pub-id></citation></ref><ref id="B102"><label>113</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vidal-Puig</surname><given-names>AJ</given-names></name><name><surname>Considine</surname><given-names>RV</given-names></name><name><surname>Jimenez-Li&#x000f1;an</surname><given-names>M</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>1997</year><volume>99</volume><issue>10</issue><fpage>2416</fpage><lpage>2422</lpage><pub-id pub-id-type="pmid">9153284</pub-id></citation></ref><ref id="B93"><label>114</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dominick</surname><given-names>MA</given-names></name><name><surname>White</surname><given-names>MR</given-names></name><name><surname>Sanderson</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR<italic>&#x003b1;</italic>/<italic>&#x003b3;</italic> agonist: evidence for urolithiasis as the inciting event in the mode of action</article-title><source><italic>Toxicologic Pathology</italic></source><year>2006</year><volume>34</volume><issue>7</issue><fpage>903</fpage><lpage>920</lpage><pub-id pub-id-type="pmid">17178691</pub-id></citation></ref><ref id="B94"><label>115</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Vleet</surname><given-names>TR</given-names></name><name><surname>White</surname><given-names>MR</given-names></name><name><surname>Sanderson</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Subchronic urinary bladder effects of muraglitazar in male rats</article-title><source><italic>Toxicological Sciences</italic></source><year>2007</year><volume>96</volume><issue>1</issue><fpage>58</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">17132713</pub-id></citation></ref><ref id="B103"><label>116</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishiu</surname><given-names>J</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Ishida</surname><given-names>Y</given-names></name><etal/></person-group><article-title>JTP-426467 acts as a selective antagonist for peroxisome proliferator-activated receptor <italic>&#x003b3;</italic> in vitro and in vivo</article-title><source><italic>Diabetes, Obesity &#x00026; Metabolism</italic></source><year>2006</year><volume>8</volume><issue>5</issue><fpage>508</fpage><lpage>516</lpage></citation></ref><ref id="B104"><label>117</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>HE</given-names></name><name><surname>Stanley</surname><given-names>TB</given-names></name><name><surname>Montana</surname><given-names>VG</given-names></name><etal/></person-group><article-title>Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR<italic>&#x003b1;</italic></article-title><source><italic>Nature</italic></source><year>2002</year><volume>415</volume><issue>6873</issue><fpage>813</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">11845213</pub-id></citation></ref><ref id="B105"><label>118</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramesh</surname><given-names>N</given-names></name><name><surname>Memarzadeh</surname><given-names>B</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium</article-title><source><italic>Molecular Therapy</italic></source><year>2004</year><volume>10</volume><issue>4</issue><fpage>697</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">15451454</pub-id></citation></ref><ref id="B106"><label>119</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bushinsky</surname><given-names>DA</given-names></name><name><surname>Favus</surname><given-names>MJ</given-names></name><name><surname>Schneider</surname><given-names>AB</given-names></name><name><surname>Sen</surname><given-names>PK</given-names></name><name><surname>Sherwood</surname><given-names>LM</given-names></name><name><surname>Coe</surname><given-names>FL</given-names></name></person-group><article-title>Effects of metabolic acidosis on PTH and 1,25(OH)2D3 response to low calcium diet</article-title><source><italic>American Journal of Physiology</italic></source><year>1982</year><volume>243</volume><issue>6</issue><fpage>F570</fpage><lpage>F575</lpage><pub-id pub-id-type="pmid">6293313</pub-id></citation></ref><ref id="B107"><label>120</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>ESC</given-names></name><name><surname>Eastmond</surname><given-names>DA</given-names></name></person-group><article-title>Effects of pH on nonenzymatic oxidation of phenylhydroquinone: potential role in urinary bladder carcinogenesis induced by <italic>o</italic>-phenylphenol in Fischer 344 rats</article-title><source><italic>Chemical Research in Toxicology</italic></source><year>1997</year><volume>10</volume><issue>7</issue><fpage>742</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">9250407</pub-id></citation></ref><ref id="B108"><label>121</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Hiraga</surname><given-names>K</given-names></name></person-group><article-title>Effects of pH on the carcinogenicity of <italic>o</italic>-phenylphenol and sodium <italic>o</italic>-phenylphenate in the rat urinary bladder</article-title><source><italic>Food and Chemical Toxicology</italic></source><year>1987</year><volume>25</volume><issue>5</issue><fpage>359</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">3609975</pub-id></citation></ref><ref id="B109"><label>122</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>St. John</surname><given-names>MK</given-names></name><name><surname>Arnold</surname><given-names>LL</given-names></name><name><surname>Anderson</surname><given-names>T</given-names></name><name><surname>Cano</surname><given-names>M</given-names></name><name><surname>Johansson</surname><given-names>SL</given-names></name><name><surname>Cohen</surname><given-names>SM</given-names></name></person-group><article-title>Dietary effects of ortho-phenylphenol and sodium ortho-phenylphenate on rat urothelium</article-title><source><italic>Toxicological Sciences</italic></source><year>2001</year><volume>59</volume><issue>2</issue><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">11158728</pub-id></citation></ref><ref id="B110"><label>123</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>AP</given-names></name><name><surname>Lina</surname><given-names>BAR</given-names></name><name><surname>Hagenaars</surname><given-names>AJM</given-names></name><name><surname>Hollanders</surname><given-names>VMH</given-names></name><name><surname>Andringa</surname><given-names>M</given-names></name><name><surname>Feron</surname><given-names>VJ</given-names></name></person-group><article-title>Effects of a dietary load of acid or base on changes induced by lactose in rats</article-title><source><italic>Food and Chemical Toxicology</italic></source><year>1995</year><volume>33</volume><issue>1</issue><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">7821870</pub-id></citation></ref><ref id="B111"><label>124</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>AP</given-names></name><name><surname>Feron</surname><given-names>VJ</given-names></name><name><surname>Immel</surname><given-names>HR</given-names></name></person-group><article-title>Induction of hyperplasia in the bladder epithelium of rats by a dietary excess of acid or base: implications for toxicity/carcinogenicity testing</article-title><source><italic>Food and Chemical Toxicology</italic></source><year>1988</year><volume>26</volume><issue>5</issue><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">3391465</pub-id></citation></ref><ref id="B112"><label>125</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>JE</given-names></name><name><surname>Kwak</surname><given-names>J-O</given-names></name><etal/></person-group><article-title>Attenuation of extracellular acidic pH-induced cyclooxygenase-2 expression by nitric oxide</article-title><source><italic>Molecules and Cells</italic></source><year>2005</year><volume>19</volume><issue>2</issue><fpage>232</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">15879708</pub-id></citation></ref><ref id="B113"><label>126</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parczyk</surname><given-names>K</given-names></name><name><surname>Kondor-Koch</surname><given-names>C</given-names></name></person-group><article-title>The influence of pH on the vesicular traffic to the surface of the polarized epithelial cell, MDCK</article-title><source><italic>European Journal of Cell Biology</italic></source><year>1989</year><volume>48</volume><issue>2</issue><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">2744008</pub-id></citation></ref><ref id="B114"><label>127</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Camacho</surname><given-names>M</given-names></name><name><surname>Machado</surname><given-names>JD</given-names></name><name><surname>Montesinos</surname><given-names>MS</given-names></name><name><surname>Criado</surname><given-names>M</given-names></name><name><surname>Borges</surname><given-names>R</given-names></name></person-group><article-title>Intragranular pH rapidly modulates exocytosis in adrenal chromaffin cells</article-title><source><italic>Journal of Neurochemistry</italic></source><year>2006</year><volume>96</volume><issue>2</issue><fpage>324</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">16336635</pub-id></citation></ref><ref id="B115"><label>128</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klempner</surname><given-names>MS</given-names></name><name><surname>Styrt</surname><given-names>B</given-names></name></person-group><article-title>Alkalinizing the intralysosomal pH inhibits degranulation of human neutrophils</article-title><source><italic>The Journal of Clinical Investigation</italic></source><year>1983</year><volume>72</volume><issue>5</issue><fpage>1793</fpage><lpage>1800</lpage><pub-id pub-id-type="pmid">6415117</pub-id></citation></ref><ref id="B116"><label>129</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Charoenphandhu</surname><given-names>N</given-names></name><name><surname>Wongdee</surname><given-names>K</given-names></name><name><surname>Tudpor</surname><given-names>K</given-names></name><name><surname>Pandaranandaka</surname><given-names>J</given-names></name><name><surname>Krishnamra</surname><given-names>N</given-names></name></person-group><article-title>Chronic metabolic acidosis upregulated claudin mRNA expression in the duodenal enterocytes of female rats</article-title><source><italic>Life Sciences</italic></source><year>2007</year><volume>80</volume><issue>19</issue><fpage>1729</fpage><lpage>1737</lpage><pub-id pub-id-type="pmid">17383680</pub-id></citation></ref><ref id="B117"><label>130</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Achanzar</surname><given-names>WE</given-names></name><name><surname>Moyer</surname><given-names>CF</given-names></name><name><surname>Marthaler</surname><given-names>LT</given-names></name><etal/></person-group><article-title>Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium</article-title><source><italic>Toxicology and Applied Pharmacology</italic></source><year>2007</year><volume>223</volume><issue>3</issue><fpage>246</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">17663016</pub-id></citation></ref><ref id="B118"><label>131</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friday</surname><given-names>E</given-names></name><name><surname>Oliver</surname><given-names>R</given-names><suffix>III</suffix></name><name><surname>Welbourne</surname><given-names>T</given-names></name><name><surname>Turturro</surname><given-names>F</given-names></name></person-group><article-title>Role of epidermal growth factor receptor (EGFR)-signaling versus cellular acidosis via Na<sup>+</sup>/H<sup>+</sup> exchanger1(NHE1)-inhibition in troglitazone-induced growth arrest of breast cancer-derived cells MCF-7</article-title><source><italic>Cellular Physiology and Biochemistry</italic></source><year>2007</year><volume>20</volume><issue>6</issue><fpage>751</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">17982257</pub-id></citation></ref><ref id="B119"><label>132</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turturro</surname><given-names>F</given-names></name><name><surname>Friday</surname><given-names>E</given-names></name><name><surname>Fowler</surname><given-names>R</given-names></name><name><surname>Surie</surname><given-names>D</given-names></name><name><surname>Welbourne</surname><given-names>T</given-names></name></person-group><article-title>Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor <italic>&#x003b3;</italic>-independent mechanism in breast cancer-derived cell lines</article-title><source><italic>Clinical Cancer Research</italic></source><year>2004</year><volume>10</volume><issue>20</issue><fpage>7022</fpage><lpage>7030</lpage><pub-id pub-id-type="pmid">15501982</pub-id></citation></ref><ref id="B120"><label>133</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welbourne</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>G</given-names></name><name><surname>Coates</surname><given-names>G</given-names></name><name><surname>Routh</surname><given-names>R</given-names></name></person-group><article-title>Troglitazone induces a cellular acidosis by inhibiting acid extrusion in cultured rat mesangial cells</article-title><source><italic>American Journal of Physiology</italic></source><year>2002</year><volume>282</volume><issue>6</issue><fpage>R1600</fpage><lpage>R1607</lpage><pub-id pub-id-type="pmid">12010740</pub-id></citation></ref><ref id="B121"><label>134</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coates</surname><given-names>G</given-names></name><name><surname>Nissim</surname><given-names>I</given-names></name><name><surname>Battarbee</surname><given-names>H</given-names></name><name><surname>Welbourne</surname><given-names>T</given-names></name></person-group><article-title>Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells</article-title><source><italic>American Journal of Physiology</italic></source><year>2002</year><volume>283</volume><issue>4</issue><fpage>E729</fpage><lpage>E737</lpage><pub-id pub-id-type="pmid">12217890</pub-id></citation></ref><ref id="B122"><label>135</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brophy</surname><given-names>JM</given-names></name></person-group><article-title>Selling safety&#x02014;lessons from muraglitazar</article-title><source><italic>The Journal of the American Medical Association</italic></source><year>2005</year><volume>294</volume><issue>20</issue><fpage>2633</fpage><lpage>2635</lpage></citation></ref><ref id="B123"><label>136</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yki-J&#x000e4;rvinen</surname><given-names>H</given-names></name></person-group><article-title>The PROactive study: some answers, many questions</article-title><source><italic>The Lancet</italic></source><year>2005</year><volume>366</volume><issue>9493</issue><fpage>1241</fpage><lpage>1242</lpage></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>					<italic>Possible mechanisms for the carcinogenic effect of dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists in the rat urothelium.</italic> (a) Simplified view ofthe rat urinary tract, showing the urothelial lining of urinary bladder,ureters, and kidney pelvis. The star in the bladder lumen indicates theexpected predilection site for urolith residence, the ventral part of thebladder. In the shown part of the urogenital tract, there are no grossanatomical differences between male and female rats. The epithelial lining iscontiguous but exhibits differentiation differences through the urogenitaltract [<xref ref-type="bibr" rid="B61">58</xref>, <xref ref-type="bibr" rid="B138">59</xref>]. Thedrawing is not to scale. (b) Four possiblemechanisms for carcinogenic effect in rat urothelium by dual-actingPPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonist.</p></caption><graphic xlink:href="PPAR2008-103167.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>					<italic>Lysis of the rat bladder urothelial cell layer in situ</italic>. (a), (b) On a fullyanesthetized rat, the bladder is exposed through an abdominal incision, a thinneedle or catheter (27G) is introduced into the bladder at the bladder neck,and ligated in place with a silk suture. (c) The bladder isemptied for urine, and filled with approximately 0.5 mL lysis solution (4 Mguanidine isothiocynate, 0.5% sarcosine, 25 mM citrate, pH 5.5), which is leftin place for 2 minutes and withdrawn. The resulting urothelial lysates can beused for RNA isolation or protein analysis by Western, as described in [<xref ref-type="bibr" rid="B11">28</xref>]. Byinfusing a trypsin solution into the bladder lumen, suspensions of urothelialcells for flow cytometric analysis can be made [<xref ref-type="bibr" rid="B13">30</xref>].</p></caption><graphic xlink:href="PPAR2008-103167.002"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>					<italic>Current mode-of-action hypothesis for the carcinogeniceffect of dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists  in the rat urothelium.</italic> To explain the carcinogenicity of dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic>agonists in the rat urothelium, we favor a multifactorial mode-of-action (MOA)hypothesis, compatible with the observation that PPAR agonists can causediametrally opposite biological effects (mitogenesis as well as cytotoxicity invitro, carcinogenicity as well as tumour inhibition in vivo) depending oncontext (species, PPAR activation profile of agonist, agonist dose, cell typeas well as PPAR expression, etc.) [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B17">33</xref>&#x02013;<xref ref-type="bibr" rid="B20">36</xref>, <xref ref-type="bibr" rid="B48">62</xref>, <xref ref-type="bibr" rid="B127">106</xref>, <xref ref-type="bibr" rid="B144">107</xref>]. (The shown MOA hypothesis is based on previously publishedragaglitazar data [<xref ref-type="bibr" rid="B36">18</xref>, <xref ref-type="bibr" rid="B11">28</xref>&#x02013;<xref ref-type="bibr" rid="B13">30</xref>, <xref ref-type="bibr" rid="B47">61</xref>], butmay be applicable to other dual-acting agonists (<xref ref-type="table" rid="tab1">Table 1</xref>) [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B14">31</xref>]. The shown MOA hypothesis is applicable to rats only dueto the known profound species differences in PPAR function [<xref ref-type="bibr" rid="B136">26</xref>, <xref ref-type="bibr" rid="B16">32</xref>]. Bladder cancer was seen in SD, Wistar, and Fischer rats of both sexes [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B12">29</xref>], butthe shown MOA hypothesis may nevertheless be rat strain dependent due to rodentstrain differences in PPAR function [<xref ref-type="bibr" rid="B124">10</xref>]. The shown MOA hypothesis is compatible with genderdifferences, due to gender differences in PPAR expression and function [<xref ref-type="bibr" rid="B97">108</xref>&#x02013;<xref ref-type="bibr" rid="B102">113</xref>], anddoes not assume urinary excretion of the PPAR agonist [<xref ref-type="bibr" rid="B25">39</xref>].)</p></caption><graphic xlink:href="PPAR2008-103167.003"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Frequency of cancer findings for PPAR agonists in rats, mice, and hamsters. The table is adaptedfrom [<xref ref-type="bibr" rid="B8">8</xref>&#x02013;<xref ref-type="bibr" rid="B124">10</xref>]and comprises rodent carcinogenicity data for between 16 and 30 PPAR<italic>&#x003b1;</italic> agonists(pharmacological as well as industrial compounds) [<xref ref-type="bibr" rid="B21">9</xref>, <xref ref-type="bibr" rid="B124">10</xref>],5 PPAR<italic>&#x003b3;</italic> agonists (pharmacological compounds only) [<xref ref-type="bibr" rid="B8">8</xref>], and 6dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists (pharmacological compounds only) [<xref ref-type="bibr" rid="B8">8</xref>]. Numbers in the cells: number of compounds causing the indicated pathology inthe indicated rodent species; M: male; F: female. The differencein rodent bladder and liver tumour frequency between PPAR<italic>&#x003b1;</italic>, PPAR<italic>&#x003b3;</italic>, and PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic>agonists is significant (<italic>P</italic> &#x0003c; .0001, Chi-square test). The difference inrodent bladder cancer frequency betwen PPAR<italic>&#x003b3;</italic> and dual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonistsis borderline significant (<italic>P</italic> = .0357 and .081 by Chi-square and Fischer'sexact tests, resp.).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><sup>(a)</sup>PPAR agonist selectivity (<italic>n</italic>, number of compounds)</th><th align="left" rowspan="1" colspan="1"><sup>(b),(f)</sup>Hemangio-sarcoma</th><th align="left" rowspan="1" colspan="1"><sup>(c),(f)</sup>Urinary bladder and renal pelvis</th><th align="left" rowspan="1" colspan="1"><sup>(d)</sup>Fibrosarcoma</th><th align="left" rowspan="1" colspan="1"><sup>(f)</sup>Lipoma and sarcoma</th><th align="left" rowspan="1" colspan="1"><sup>(e),(f)</sup>Liver</th><th align="center" rowspan="1" colspan="1">Other</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>PPAR<italic>&#x003b1;</italic> agonists</italic>  (<italic>n</italic> = 30 for hepatocarcinogenicity, <italic>n</italic> = 16 for extrahepatic tumours)</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">30 of 30, in mice or rats</td><td align="left" rowspan="1" colspan="1">Typically pancreatic acinar cell and Leydig cell tumours. Thyroid and lung tumours and  leukaemia also described.								</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>PPAR<italic>&#x003b3;</italic> agonists</italic> (<italic>n</italic> = 5)</td><td align="left" rowspan="1" colspan="1">3 (mice, M and F)</td><td align="left" rowspan="1" colspan="1">1 (rats, M and F)</td><td align="left" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1">3 (rats, M and F)</td><td align="left" rowspan="1" colspan="1">2 (rats and mice, F)</td><td align="left" rowspan="1" colspan="1">1 (mice, gallbladder adenoma). 1 (rats, stomach, leiomyosarcoma).								</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Dual acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists</italic> (<italic>n</italic> = 6)</td><td align="left" rowspan="1" colspan="1">5 (mice, M and F, hamster, M)</td><td align="left" rowspan="1" colspan="1">5 (rats, M and F)</td><td align="left" rowspan="1" colspan="1">2 (rats, M and F)</td><td align="left" rowspan="1" colspan="1">2 (rats, mice, M and F)</td><td align="left" rowspan="1" colspan="1">3 (rats, mice, M and F)</td><td align="left" rowspan="1" colspan="1">1 (rats, testicular). 1 (rats, mammary). 1 (mice, mammary and stomach). 1 (rats, thyroid). 1 (rats, uterine). 1 (rats, uterine and leukaemia).</td></tr></tbody></table><table-wrap-foot><fn><p>						<sup>(a)</sup>Comparativedata for PPAR selectivity are lacking. No study has to our knowledge for apanel of PPAR agonists compared activity on all PPAR isoforms, between rats,mice, and humans, in the relevant cell type, for example, hepatocyte orurothelial. However, it is clear that selective PPAR<italic>&#x003b3;</italic> agonists may havesignificant PPAR<italic>&#x003b1;</italic> activity [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B9">11</xref>].</p><p>						<sup>(b)</sup> Miceappear to be more sensitive to the effect of PPAR<italic>&#x003b3;</italic> agonists than rats [<xref ref-type="bibr" rid="B128">12</xref>].</p><p>						<sup>(c)</sup>Raturothelium may be more sensitive to the carcinogenic effect of dual-actingPPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonists than mouse urothelium. Bladder cancer was seen in SD, Wistar,and Fischer rats of both sexes [<xref ref-type="bibr" rid="B8">8</xref>]. Renalproximal tubular carcinoma was also observed with 2 dual agonists(undifferentiated sarcomatous tumours) [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>						<sup>(d)</sup>Onedual-acting PPAR<italic>&#x003b1;</italic>+<italic>&#x003b3;</italic> agonist for which fibrosarcoma has been described istesaglitazar [<xref ref-type="bibr" rid="B15">13</xref>].</p><p>						<sup>(e)</sup>OnePPAR<italic>&#x003b3;</italic> agonist for which hepatocarcinogenesis has been described is troglitazone[<xref ref-type="bibr" rid="B129">14</xref>].</p><p>						<sup>(f)</sup>PPAR<italic>&#x003b1;</italic>and PPAR<italic>&#x003b3;</italic> are typically described as having a tissue-restricted expression,with PPAR<italic>&#x003b2;</italic> expression being more ubiquitous [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B95">15</xref>, <xref ref-type="bibr" rid="B130">16</xref>]. Endothelial as well as urothelial cells coexpress PPAR<italic>&#x003b1;</italic> and PPAR<italic>&#x003b3;</italic> isoforms [<xref ref-type="bibr" rid="B24">17</xref>&#x02013;<xref ref-type="bibr" rid="B96">20</xref>]. White fat expresses mostly PPAR<italic>&#x003b3;</italic> [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B95">15</xref>, <xref ref-type="bibr" rid="B130">16</xref>],but it is increasingly recognized that PPAR<italic>&#x003b1;</italic> may also have function in whitefat [<xref ref-type="bibr" rid="B131">21</xref>]. Liverexpresses mostly PPAR<italic>&#x003b1;</italic> [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B95">15</xref>, <xref ref-type="bibr" rid="B130">16</xref>],but it is increasingly recognized that PPAR<italic>&#x003b3;</italic> may also have function in theliver [<xref ref-type="bibr" rid="B132">22</xref>&#x02013;<xref ref-type="bibr" rid="B136">26</xref>].</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>